Annals of Oncology 8: 1285–1303, 1997.

Index of subjects Volume 8 (1997)

A

abdominal surgery
for gastrointestinal tumors in elderly patients (Review) 317

accelerated radiotherapy
combined with chemotherapy 681
for patients with head and neck cancer 681
toxicity and treatment results 681

acute dyspnoea
as a side effect of vinorelbine (Letter to the editor) 503

acute myeloid leukemia
in adults 251
treatment with high-dose *versus* standard-dose cytarabine 251

acute myelomonocytic leukemia
extravasion of anthracyclines (Letter to the editor) 1167

acute promyelocytic leukemia
in elderly patients (Short report) 1273
treatment with all-trans-retinoic acid (Short report) 1273

adjuvant chemotherapy
combined with surgery 751
for patients with premenopausal node-positive breast cancer 751

adjuvant therapy
cost-effectiveness 65
in breast cancer (Special article) 825, S3: 3
in Dukes' B and C colorectal carcinoma 65
quality of life assessment (Special article) 825

adolescence
treatment of anaplastic large-cell lymphoma S1: 37

adrenocortical carcinoma
treatment with mitotane (Review) 423

advanced disease
treatment with formestane 649

advanced gastric cancer
treatment with mitomycin C (Short report) 294
treatment with oral etoposide (Short report) 294

advanced Hodgkin's disease
treatment with chemotherapy (Letter to the editor) 1281

advanced non-small-cell lung cancer
nephrotoxicity (Short report) 709
treatment with combination chemotherapy (Short report) 709
treatment with modified MIC (Short report) 709

advanced ovarian cancer
dose intensity (Editorial) 311
first-line treatment (Short report) 803
treatment with paclitaxel (Short report) 803

advanced pancreatic cancer
treatment with chemotherapy (Editorial) 415

age
effect on characteristics and clinical behavior of non-Hodgkin's lymphoma patients 973

aggresive non-Hodgkin's lymphoma
cellular and molecular features S1: 43
heterogeneity in outcomes S1: 43
prognostic factors S1: 43

AIDS
associated with Kaposi's sarcoma 871
involvement of the *bcl-6* gene S2: 105
treatment with interleukin-4 79

AILD
treatment with cyclosporine (Short report) 601

ALK antigen
used for the characterization of anaplastic large-cell lymphoma S1: 37

allogeneic bone marrow transplantation
in patients with chronic myeloid leukaemia (Clinical case) 91

α-interferon
for patients with chronic myeloid leukaemia (Clinical case) 91
for patients with MALT lymphomas 883

ambulatory chemotherapy
for patients with gastrointestinal cancer (Special article) 111

9-aminocamptothecin
for patients with non-Hodgkin's lymphoma S1: 119

amyloidosis
in non-Hodgkin's lymphoma 267

anemia
caused by dose-intensive chemotherapy (Review) S3: 7
role of recombinant growth factors (Review) S3: 7

anal canal cancer
treatment with high-dose radiation therapy and chemotherapy 575

analgesic use
as a post-radiative treatment (Review) S3: 25

anaplasia
use of anti-ALK antibody S1: 37

anaplastic large-cell lymphoma
amplification of genomic DNA S2: 59
characterization by anti-ALK antibody S1: 37
clinico-pathologic study 583
detection of t(2;5)(p23;q35) S2: 59, 65
in childhood S1: 37
REAL classification 583
use of fluorescent *in situ* hybridization S2: 65

angioimmunoblastic T-cell lymphoma
treatment with cyclosporine (Short report) 601

anthracyclines
combined with paclitaxel (Review) 939
dose intensity (Editorial) 1177
for patients with breast cancer (Review) 939

antiangiogenesis
paracrine imbalance (Clinical case) 1031

anticancer therapy
cell signaling (Commentary) 429

anticoagulation
for treatment of cancer-related thromboembolic disease 669

antisense
inhibiting c-*myc* expression S1: 25
treatment for patients with Burkitt's lymphoma S1: 25

antisense DNA
use in anti-melanoma gene therapy 1257

anti-Yo autoantibody
paraneoplastic temporal lobe epilepsy (Letter to the editor) 919

apoptosis
activation by distinct target-cell cytoplasmic proteases S2: 75
activation by cytotoxic chemotherapy (Clinical case) 1031
induction in patients with tumor stabilization and biochemical response (Short report) 1041
aromatase inhibitors
as a therapy for breast cancer (Editorial) 631, 649
ATase
correlation with clinical and prognostic characteristics 335
predicting response to therapy in breast cancer 335
ataxia
following docetaxel infusion (Letter to the editor) 812
attributable risks
due to psoralens (Arena) 435
for melanoma (Arena) 435
autograft
in patients with advanced large-cell lymphomas S1: 63
autologous bone marrow transplantation (ABMT)
combined with salvage therapy with mini-BEAM 675
cost-effectiveness (Short report) 1277
in chronic myeloid leukaemia (Clinical case) 91
in Hodgkin's disease 785, (Short report) 1277
in non-Hodgkin's lymphoma 675
autologous transplant
combined with intensive chemotherapy (Short report) 701
for patients with mantle cell lymphoma (Short report) 701
autotransplants
combined with high-dose chemotherapy (Editorial) 933
AZT
maximal tolerable doses 539
for patients with metastatic colorectal cancer 539
in combination with 5-fluorouracil and leucovorin 539

B

bacterial flora
detection in primary gastric lymphomas S2: 33
BAGE
in patients with breast cancer 369
B-cell
role in tumor development S1: 83
B-cell chronic lymphocytic leukemia
biology, diagnosis and therapy S1: 93
bcl-1
as a prognostic factor for malignant lymphomas S2: 109
bcl-2
as a prognostic factor for survival of ovarian cancer patients 469
role in morphologic transformation of follicular lymphoma S2: 119
somatic mutations S2: 119
bcl-6
role in AIDS-related lymphomas S2: 105
role in Burkitt's lymphoma 987
BEACOPP
for patients with advanced Hodgkin's disease (Rapid publication) 143
benign breast disease
increased risk of breast cancer (Short report) 297
bilirubin
relation with CPT-11 toxicity (Short report) 1049
biochemical modulation
of 5-fluorouracil by PALA and MTX (Short report) 917
role of interferon (Arena) 139
role of levo-leucovorin 169
biological transport
by erythrocytes 1139
of activated oxazaphosphorines 1139
biology (Commentary) 27
biomarkers
of lymphoma risks S2: 45
bisphosphonates
efficacy in hypercalcemia of malignancy and local toxicity (Short report) 915
hypodermoclysis (Short report) 915
role in metastatic bone disease 1243
blastic phase of chronic myelogenous leukemia
bone marrow transplantation 175
combination therapy 175
blood specimen collection
in the erythrocyte compartment 1139
bolus chemotherapy
versus infusion chemotherapy (Review) 15
body cavity-based lymphoma
role of Kaposi's sarcoma-associated herpesvirus S2: 123
bone
malignant fibrous histiocytoma 1107
bone marrow transplantation
combined with peripheral blood stem cell transplantation (Editorial) 219
diets (Special article) 223
in patients with chronic myelogenous leukemia 175
in patients with multiple myeloma (Editorial) 219
oligoclonal or monoclonal lymphomas S2: 137
role of EBV S2: 137
versus radioimmunotherapy S1: 133
bone metastases
treatment with pamidronate 1243
bone resorption
new markers in patients with bone metastases 1243
brachytherapy
combined with limited surgery 1089
for patients with squamous cell carcinoma of the penis 1089
brain metastasis
treatment with chemo-radiotherapy (Short report) 911
brain neoplasms
in immunocompetent patients (Review) 227
breast cancer
adjuvant therapy (Special article) 825, S3: 3
axillary dissection 757
conservative treatment 235, 757
cost-effectiveness of treatments 757
dose intensity (Editorial) 109, 655
drug resistance markers (Editorial) 314, 335
neutropenic enterocolitis (Letter to the editor) 405
postmenopausal 745
premenopausal 751
quality of life assessment (Special article) 825
response predictions 335
risk factors for local recurrence 235
sector resection 767

sexual functioning (Editorial) 105, 149, (Letter to the editor) 616
timing of breast surgery 751
treatment with
adjuvant CMF 271
anthracycline (Editorial) 1177
anthracyclines and paclitaxel (Review) 939
aromatase inhibitors (Editorial) 631, 649
chemotherapy (Letter to the editor) 616
doxorubicin and cyclophosphamide 957
epirubicin 1213
high-dose chemotherapy 957
formestane 649
paclitaxel and cyclophosphamide 655
postoperative radiotherapy 757
radiation therapy (Editorial) 217
thymidine phosphorylase 271
vinorelbine combined with 5-fluorouracil and folinic acid 865
vorozole 745
breast cancer risk
after diagnosis of fibroadenoma (Short report) 297
breast conservation therapy
and radiation therapy (Editorial) 217
breast neoplasm
treatment with epirubicin monotherapy 1213
bronchoalveolar lavage
as an indication for pulmonary infiltration (Clinical case) 905
bryostatin
for patients with non-Hodgkin's lymphoma S1: 119
Burkitt's lymphoma
c-*myc* expression S1: 25, 31
detection of translocations by PCR S1: 31
effects of antisense oligodeoxynucleotides S1: 25
event-free survival S1: 77
in children S1: 31, 77
pediatric *versus* adult patients S1: 77

C

cachexia
in patients with endocrine-insensitive advanced cancer 277
treatment with megestrol acetate 277
camptothecin analogues
clinical evaluation (Review) 837
camptothecin derivative
in patients with untreated non-small-cell lung carcinoma 1003
cancer
causing thromboembolic disease 669
epidermal growth factor (Review) 1197
ethical issues (Arena) 945
strategies (Review) 1063
topoisomerase I inhibitors (Review) 837
cancer control
European Cancer Experts recommendations (Special article) 9
cancer fatigue
correlation with physical performance 1251
cancer in the elderly
elective surgery (Review) 317
cancer pain
therapy (Review) S3: 15
cancer prevention
environmental pollution (Commentary) 137
European Cancer Experts recommendations (Special article) 9
cancer therapy
new approaches S1: 139
carboplatin
after intrapleural combination treatment 385
clearance (Short report) 607
combined with paclitaxel (Short report) 697
dose adaptation (Short report) 607
five *versus* eight courses 327
for obese patients (Short report) 607
in advanced epithelial ovarian carcinoma 327, 355
in advanced pancreatic carcinoma 439
in chronic myelogenous leukemia 175
in head and neck cancer 451
in malignant pleural effusion 385
in non-small-cell lung cancer (Short report) 697
in ovarian cancer 351
in combination with
cisplatin 385
paclitaxel 351, 355, 451
protracted infusional 5-fluorouracil 439
carcinogenesis
from environmental pollution (Commentary) 137
carcinoid tumor
prognostic factors 685
survival rate 685
cardiac arrhythmias
after cisplatin infusion (Clinical case) 1263
cardiac diseases
as a complication of Hodgkin's disease therapy (Arena) 115
cardiotoxicity
of 5-fluorouracil and folinic acid (Short report) 705
CB/CC diffuse lymphoma
as a subtype of non-Hodgkin's lymphoma S2: 25
CD4/CD8 ratio
predicting the outcome of interferon-α therapy 71
CD8+ T-cells
cytotoxicity S2: 75
immunity S2: 75
CD30L
expression in lymph nodes involved with Hodgkin's disease S2: 97
CD30 antigen
characterization by anti-ALK antibody S1: 37
CD34+ progenitor cells
detection of trisomy 12 S2: 55
in a patient with chronic lymphocytic leukemia 55
CD40L
expression in lymph nodes involved with Hodgkin's disease S2: 97
cell cycle
in mantle-cell lymphoma pathogenesis S2: 71
cell differentiation
mechanisms (Clinical case) 1031
cell signaling
as a tool against cancer (Commentary) 429
central nervous system recurrence
of lymphoid malignancies (Review) 515

treatment with high-dose chemotherapy (Review) 515
centrocytic lymphomas
role of *bcl*-1 S2: 109
changing incidence
of non-Hodgkin's lymphoma in Europe S2: 49
chemo-radiotherapy
for patients with head and neck cancer 773
chemotherapy
BEACOPP (Rapid publication) 143
causing cardiac arrhythmias (Clinical case) 1263
combined with accelerated radiotherapy 681
control of onset nausea and vomiting 181
for children with Hodgkin's disease (Editorial) 215, S1: 15
in adrenocortical carcinoma (Review) 423
in advanced epithelial ovarian cancer 355
in advanced gastric cancer 163
in advanced Hodgkin's disease (Rapid publication) 143, 259, (Letter to the editor) 1281
in advanced malignant melanoma 363
in advanced non-small-cell lung cancer (Short report) 1269
in advanced pancreatic cancer (Editorial) 415
in advanced sarcomas (Arena) 637
in advanced solid tumors (Short report) 291
in advanced urothelial cancer 373, (Short report) 695
in breast cancer 271, 865, 1213
in colorectal cancer (Clinical case) 393
in Ewing's family tumors 1099
in head and neck cancer (Editorial) 417, 451, 681
in hepatocellular carcinoma (Short report) 500
in Hodgkin's disease S1: 111
in malignant lymphoma S1: 107
in metastatic non-seminomatous germ cell tumors 477
in multimodality treatment (Clinical case) 691
in non-Hodgkin's lymphoma S1: 67, 71, 119
in non-small-cell lung cancer (Clinical case) 285, 697
in PPNET (Clinical case) 691
in primary central nervous system lymphoma (Review) 227
in seminoma 37
in UCNT 739
late relapse of germ cell tumors 41
pediatric 1099
role of the 5-HT_3 antagonists 181
strategies (Review) 1063
versus best supportive care 163
VIP-E therapy for patients with non-small-cell lung cancer 49
VIP-E therapy for patients with small-cell lung cancer 57
children
occurrence of long-term pulmonary sequelae S1: 19
treatment of
anaplastic large-cell lymphoma (Arena) 37
Burkitt's lymphoma S1: 31
Hodgkin's disease S1: 19
Hodgkin's disease with chemotherapy (Editorial) 215, S1: 15
Hodgkin's disease without radiotherapy S1: 15
lymphomas S1: 7
non-Hodgkin's disease in India 893
treatment with chemotherapy 893
CHOP therapy
for patients with non-Hodgkin's lymphoma S1: 61, 71
chromogranin
as a prognostic factor for carcinoid tumors 685
reducement after high-dose chemotherapy (Short report) 1041
chromosomal translocations
detection of the role of *bcl*-6 protein expression S2: 101
chronic lymphocytic leukemia
detection of trisomy 12 in CD34+ progenitor cells S2: 55
fulminant cardiac tamponade (Letter to the editor) 1168
chronic myeloid leukemia
bone marrow transplantation 175
management problems (Clinical case) 91
CHVmP-VB
for patients with non-Hodgkin's lymphoma S1: 67
cisplatin
accumulation in leukocytes and tumor cell lines 1145
after intrapleural combination treatment 385
causing cardiac arrhythmias (Clinical case) 1263
combined with
carboplatin 385
etoposide and i.v. sodium thiosulphate protection 1235
5-fluorouracil 575, (Letter to the editor) 713
gemcitabine and vinorelbine (Short report) 1045
leucovorin (Letter to the editor) 713
molgramostim (Arena) 637
ondansetron, methylprednisolone and metopizamine 887
paclitaxel 663, (Short report) 1157
radiotherapy 575
tirapazamine 363, (Short report) 1269
topotecan 1003
zorubicin 739
five *versus* eight courses 327
in advanced epithelial ovarian carcinoma 327
in advanced malignant melanoma 363
in advanced non-small-cell lung cancer (Short report) 1269
in advanced sarcomas (Arena) 637
in advanced solid tumors (Short report) 291
in anal canal cancer 575
in germ cell tumors 41
in head and neck cancer 445, 713, (Short report) 1157
in malignant pleural effusion 385
in metastatic breast cancer 663
in non-small-cell lung cancer 525, 1003, (Short report) 1045
in ovarian cancer 569, 1235
in seminoma 37
in UCNT 739
for symptom control in cell carcinoma of the head and neck 445
intraperitoneal 1235
toxicity 569, 1003
versus single-agent gemcitabine 525
cisplatin-based chemotherapy
for patients with mediastinal non-seminomatous germ cell tumors 555
cisplatin-refractory patients
with germ cell tumors 1229
cladrabine
for patients with non-Hodgkin's lymphoma S1: 119
classification
of lymphomas S2: 3, 11

of NK-cell neoplasms S2: 17
of peripheral T-cell lymphomas 583
of T-cell neoplasms S2: 17
revised S2: 11
Clinical cases
allogeneic bone marrow transplantation
in patients with chronic myeloid leukaemia 91
α-interferon
in patients with chronic myeloid leukaemia 91
antiangiogenesis
paracrine imbalance 1031
apoptosis
activation by cytotoxic chemotherapy 1031
autologous bone marrow transplantation
in patients with chronic myeloid leukaemia 91
bronchoalveolar lavage
as an indication for pulmonary infiltration 905
cardiac arrhythmias
after cisplatin infusion 1263
cell differentiation
mechanisms 1031
chemotherapy
causing cardiac arrhythmias 1263
in colorectal cancer 393
in multimodality treatment 691
in non-small-cell lung cancer 285
in PPNET 691
chronic myeloid leukemia
management problems 91
cisplatin
causing cardiac arrhythmias 1263
colon cancer
hereditary 1151
colorectal cancer
surgery 393
treatment with chemotherapy 393
differential radiological diagnosis
of meningeal plasmacytomas 791
docetaxel
causing interstitial pulmonary injury 191
drug-induced toxicity
after treatment with docetaxel 191
hereditary nonpolyposis colorectal cancer
recent discoveries 1151
high-dose therapy
in multimodality treatment 691
for patients with PPNET 691
histopathological findings
to document plasma cell tumors 791
Hodgkin's disease
neurological complications 593
interstitial pneumonitis
after treatment with docetaxel 191
liver metastases
from colorectal cancer 393
lung cancer
complete spontaneous remission 1031
treatment with chemotherapy 285
treatment with docetaxel 191
Lynch syndrome
recent discoveries 1151
magnesium depletion
caused by cisplatin infusion 1263
multiple myeloma
compared with plasmacytomas 791
myelodysplasia
relation with pulmonary infiltration 905
neurological complications
of Hodgkin's disease 593
neutrophilia
relation with pulmonary infiltration 905
peripheral blood progenitor cell support
in patients with chronic myeloid leukaemia 91
PPNET
treatment with multimodality therapy 691
progressive multifocal leukoencephalopathy
due to Hodgkin's disease 593
pulmonary infiltration
associated with myelodysplasia 905
side effects
of cisplatin infusion 1263
solitary plasmacytoma
compared to other meningeal tumors 791
problems with radiological diagnosis 791
spontaneous remission
in a patient with metastatic non-small-cell lung cancer 1031
stem cell transplantation
for patients with PPNET 691
surgical approach
to colorectal cancer 393
Sweet's syndrome
associated with pulmonary infiltration 905
clinical decision making
on quality of life (Arena) 1207
clinical efficacy
of treatment with vorozole for breast cancer 745
clinical phenotype
of CB/CC diffuse lymphomas S2: 25
clinical trial
CONSORT (Editorial) 511
of patients receiving emetogenic chemotherapy 181
role of ondansetron and dolasetron in the control of nausea 181
clinics
study of peripheral T-cell lymphoma-cases 583
CLL biology
recent progress S1: 93
CLL diagnosis
recent progress S1: 93
CLL therapy
recent progress S1: 93
clodronate
efficacy in hypercalcemia of malignancy and local toxicity (Short report) 915
clonal heterogeneity
rare expression of NMP/ALK S2: 83
c-myc

implications for Burkitt's lymphoma 987, S1: 25, 31
colon cancer
hereditary (Clinical case) 1151
colorectal cancer
assessing the effectiveness of follow-up care (Editorial) 1059
cost-effectiveness 1081
surgery (Clinical case) 393
treatment with
adjuvant therapy 65
chemotherapy (Clinical case) 393
5-fluorouracil and mitomycin C 995
5-fluorouracil and pulsed folinic acid (Short report) 1163
interferon (Arena) 139
levo-leucovorin 169
combination chemotherapy
for patients with advanced non-small-cell lung cancer (Short report) 709, 1003
for patients with uterine carcinoma 969
nephrotoxicity (Short report) 709
combined treatment
in brain metastases (Short report) 911
in lung cancer (Short report) 911
in primary central nervous system lymphoma (Review) 227
complications
cancer-related thromboembolic disease 669
of cancer treatment 669
of Hodgkin's disease S1: 115
computed tomography
staging patients with mediastinal Hodgkin's disease S1: 53
conservative treatment
for patients with large-cell lymphoma of the stomach (Short report) 497
for patients with stage I breast cancer 235, 757
CONSORT
basic standards for clinical trials (Editorial) 511
continuous infusion
for patients with soft tissue sarcomas (Short report) 1159
of high-dose ifosfamide (Short report) 1159
cost-effectiveness analysis
of adjuvant therapy for colorectal carcinoma 65
of a follow-up program in colorectal cancer 1081
of melphalan salvage therapy for Hodgkin's disease (Short report) 1277
of postoperative radiotherapy for breast cancer 757
CPT-11
clinical evaluation (Review) 837
toxicity in patients with Gilbert's syndrome (Short report) 1049
Cremophor
combined with paclitaxel (Short report) 611
reducing cisplatin concentration in leukocytes 1145
cross-cultural issues
regarding quality of life assessment (Short report) 825
cutaneous lymphoma
pathobiology, classification and treatment S1: 83
cyclin D1
overexpression as characterization for mantle-cell lymphomas S2: 71, 109
cyclin-dependent kinase inhibitors
in chronic lymphocytic leukemia S2: 71
in mantle-cell lymphomas S2: 71
cyclophosphamide
combined with doxorubicin 957
combined with paclitaxel 655
for patients with advanced breast cancer 655, 957
cyclosporine
for patients with angioimmunoblastic T-cell lymphoma (Short report) 601
cytarabine ara-C high dose
for patients with acute myeloid leukaemia 251
cytotoxic T-cell
classification S2: 17
new approaches S2: 75
cytotoxic T lymphomas
human EBV-specific S2: 137
use for adoptive chemotherapy S2: 137

D

delayed anaemia
treatment with epoetin alfa (Review) S3: 11
delayed emesis
induced by moderately emetogenic chemotherapy 561
delayed nausea
cisplatin-induced (Letter to the editor) 611
prevention (Letter to the editor) 615
dexamethasone
as a treatment against paclitaxel-related hypersensitivity (Short report) 611
in combination with paclitaxel (Short report) 611
diagnosis
of anaplastic large-cell lymphoma in children S1: 37
of pediatric lymphomas S1: 7
of primary B-cell lymphomas of the skin S2: 29
diets
anticancer properties (Special article) 223
differential radiological diagnosis
of meningeal plasmacytomas (Clinical case) 791
diffuse large-cell lymphoma
caused by morphologic transformation of follicular lymphomas S2: 119
role of bcl-2 S2: 119
DNA
AZT-induced 539
docetaxel
antitumor activity (Editorial) 1183
antitumor efficacy in nude mice 1221
causing interstitial pulmonary injury (Clinical case) 191
causing severe peripheral neuropathy 187
combined with paclitaxel 1221
compared to paclitaxel (Editorial) 1183
for patients with non-Hodgkin's lymphoma S1: 119
docetaxel infusion
followed by ataxia (Letter to the editor) 812
dose adaptation
of carboplatin (Short report) 607
dose intensity
for bolus *versus* infusion chemotherapy (Review) 15
for five *versus* eight courses of cisplatin/carboplatin 327
in advanced epithelial ovarian carcinoma 327
in advanced ovarian cancer (Editorial) 311
in Ewing's family tumors 1099
in metastatic breast cancer (Editorial) 109, 155

in non-Hodgkin's lymphoma S1: 71
dosing schedule
for Filgrastim on hematologic recovery following chemotherapy 1117
double-staining
to visualize co-expression of factor and receptor 1023
doxorubicin
combined with cyclophosphamide 957
combined with molgramostim (Arena) 637
for patients with advanced sarcomas (Arena) 637
for patients with metastatic breast cancer 957
drug-accumulation
in leukocytes and tumor cell lines 1145
drug-induced toxicity
after treatment with docetaxel (Clinical case) 191
drug resistance markers
correlation with clinical and prognostic characteristics 335
in breast cancer (Editorial) 314, 335
in ovarian cancer (Editorial) 314

E

early detection
of melanoma (Arena) 435
Eastern and Central Europe
carcinogenesis from environmental pollution (Commentary) 137
economic costs
of post-remission therapy 251
of high-dose *versus* standard-dose cytarabine 251
elderly patients
effect on characteristics and clinical behavior of non-Hodgkin's lymphoma 973
role of all-trans-retinoic acid treatment (Short report) 1273
with acute promyelocytic leukemia (Short report) 1273
endocrine activity
of treatment with vorozole for breast cancer 745
emesis
role of 5-HT_3 antagonists 181
treatment with cisplatin-based chemotherapy 887
environmental pollution
carcinogenesis (Commentary) 137
EORTC
trial to study the effect of CHVmP on non-Hodgkin's lymphoma S1: 67
eosinophils
role in the pathobiology of Hodgkin's disease S2: 89
epidemiology
environmental pollution (Commentary) 137
in Eastern and Central Europe (Commentary) 137
of non-Hodgkin's lymphoma in Europe S2: 49
epidermal growth factor receptor
function and role in clinical trials (Review) 1197
epirubicin
combined with 5-fluorouracil and l-leucovorin (Short report) 797
for patients with advanced pancreatic cancer (Short report) 797
for patients with metastatic breast cancer 155, 1213
epithelial ovarian cancer
second-look surgery (Editorial) 627
treatment with intraperitoneal cisplatin and etoposide 1235
epoetin alfa
combined with dose-intensive therapy (Review) S3: 7, 13
in autologous bone marrow transplantation (Review) S3: 7
in delayed anaemia (Review) S3: 11
in peripheral blood stem cell (Review) S3: 7
use before high-dose chemotherapy (Review) S3: 13
Epstein–Barr virus
and pyothorax-associated lymphoma 1133
in patients with Burkitt's lymphomas 987, S2: 131
in patients with gastric lymphoma S2: 41
induced lymphoproliferations in xenografted SCID mice S2: 137
specific cytotoxic T lymphocytes S2: 137
use for adoptive chemotherapy S2: 137
Epstein–Barr virus-associated lymphomas
chromosome instability S2: 131
erythrocytes
as carriers of compounds 1139
transporting activated oxazaphosphorines 1139
esophageal neoplasms
management of secretions (Short report) 198
etoposide
for patients with lung cancer 485
for patients with non-small-cell lung cancer 525
in combination with cisplatin 525
in combination with paclitaxel 485
versus single-agent gemcitabine 525
Ewing's sarcoma
treatment with pediatric chemotherapy 1099
extranodal lymphomas
treatment with combined therapy (Review) 227
extranodal non-Hodgkin's lymphomas
definition (Review) 727
extragonadal
germ cell tumors 555

F

Fas
role in CTL-mediated lysis S2: 75
FasL
expression in Hodgkin's disease nodal lymphocytes S2: 97
fibroadenoma
increased risk of breast cancer (Short report) 297
Filgrastim
dosing schedule 1117
first-line treatment
for patients with advanced ovarian cancer (Short report) 803
FISH
analyzing the physical status of EBV S2: 131
5-fluorouracil
biological modulation by PALA and MTX (Short report) 917
cardiotoxicity (Short report) 705
combined with
cisplatin 575, (Letter to the editor) 713
epirubicin and l-leucovorin (Short report) 797
folinic acid (Short report) 705
leucovorin (Letter to the editor) 713
mytomycin C 995
pulsed folinic acid (Short report) 1163
radiotherapy 575
vinorelbine and folinic acid 865

in advanced colorectal cancer 169, (Letter to the editor) 203, 995
in advanced pancreatic cancer (Short report) 797, (Short report) 917
in anal canal cancer 575
in biochemical modulation (Arena) 139, 169
in breast cancer 865
in colorectal cancer (Short report) 1163
in gastrointestinal cancers (Special article) 111
in head and neck cancer (Letter to the editor) 713
treatment planning (Letter to the editor) 203
5-HT_3 antagonists
in emetogenic chemotherapy 181
in radiotherapy (Letter to the editor) 302
role in the control of onset nausea 181
fludarabine
for patients with non-Hodgkin's lymphoma S1: 119
fluorescent *in situ* hybridization
detecting t(2;5)(p23;q35) in anaplastic large-cell lymphoma S2: 65
18-fluorodeoxyglucose (FDG)
combined with PET S1: 57
for diagnosis of residual mass in patients with lymphoma S1: 57
fluorouracil
for patients with advanced pancreatic carcinoma 439
for patients with metastatic colorectal cancer 539
in combination with AZT and leucovorin 539
in combination with carboplatin 439
fludarabine
combined with mitoxantrone 379
for patients with non-Hodgkin's disease 379
folinic acid
cardiotoxicity (Short report) 705
combined with vinorelbine and 5-fluorouracil 865
for patients with breast cancer 865
follicular lymphomas
morphological transformation S2: 119
novel therapeutic strategies S1: 89
role of the *bcl*-2 gene S2: 119
follow-up
cost-effectiveness 1081
of patients treated for colorectal cancer 1081
formestane
for patients with breast cancer 649

G

gallium scan
staging patients with mediastinal Hodgkin's disease S1: 53
gastric cancer
treatment with best supportive care 163
treatment with chemotherapy 163
gastric lymphomas
infection with *Helicobacter pylori* S2: 37, 41
pathogenesis S2: 41
surgery (Editorial) 419
treatment with chemotherapy (Short report) 497
gastrointestinal lymphoma
high-dose treatment with lanreotide (Short report) 1041
histological features, sites of involvement and management S1: 85
gastrointestinal neoplasms
elective surgery (Editorial) 317
in elderly patients (Editorial) 317
gastrointestinal tract
definition (Review) 727
G-CSF
for patients with advanced breast cancer 655
gemcitabine
combined with cisplatin and vinorelbine (Short report) 1045
for patients with non-small-cell lung cancer (Short report) 1045
genetic abnormalities
in patients with adrenocortical carcinoma (Review) 423
genetic instability
correlation with lymphoma risk S2: 45
genetic lesion
characterizing AIDS-NHL S2: 105
genetic screening
ethical issues (Arena) 945
genistein
anticancer properties (Special article) 223
genitourinary tract
definition (Review) 727
germ cell tumor
treatment with
cisplatin-based chemotherapy 41, 1229
cisplatin-based combination chemotherapy 555
cyclical POMB/ACE chemotherapy 477
germinal center
proliferation with antigen-activated B-cells S2: 79
gliomas
growth factors 1023
glucuronidation
relation with CPT-11 toxicity (Short report) 1049
glutathione
for patients treated with cisplatin 569
improving quality of life 569
reducing toxicity 569
glutathione S-transferase
in epithelial ovarian cancer 343
response to chemotherapy 343
glycopyrrolate
controlling secretions in patients with esophageal cancer (Short report) 198
treatment for patients with esophageal cancer (Short report) 198
Gompertzian kinetics
use for planning treatment for breast cancer (Arena) 1057
GPx
correlation with clinical and prognostic characteristics 335
predicting response to therapy in breast cancer 335
growth factor receptors
anticancer therapy (Commentary) 429
growth factors
in human gliomas 1023
role of perlecan 1257
GSH
correlation with clinical and prognostic characteristics 335
predicting response to therapy in breast cancer 335
GST
correlation with clinical and prognostic characteristics 335

predicting response to therapy in breast cancer 335

H

hairy-cell leukemia
role of *bcl*-1 S2: 109
head and neck cancer
symptom control 445
treatment with
chemotherapy (Editorial) 417, 445, 451
chemotherapy combined with accelerated radiotherapy 681
cisplatin and fluorouracil combined with radiotherapy 773
cisplatin and paclitaxel (Short report) 1157
neoadjuvant chemotherapy (Letter to the editor) 713
paclitaxel and carboplatin 451
Helicobacter pylori
detection in primary gastric lymphomas S2: 33
in patients with gastric lymphoma S2: 37, 41
hematopoietic cells
effect of paclitaxel and docetaxel 1145
hematopoietic growth-factor support
for patients with non-small-cell lung cancer 57
for patients with small-cell lung cancer 49
with chemotherapy dose intensification 49
hematopoietic progenitor-cell support
for patients with solid tumors 951
hepatitis B
as the cause for fatal hepatic failure S1: 107
hepatitis B virus carriers
in the treatment of malignant lymphomas S1: 107
hepatocellular carcinoma
randomized controlled trials (Review) 117
treatment (Review) 117
treatment with raltitrexed (Tomudex) (Short report) 500
hereditary nonpolyposis colorectal cancer
recent discoveries (Clinical case) 1151
high-dose chemotherapy
combined with
autologous stem cell transplantation (Short report) 401
autotransplants (Editorial) 933
epoetin alfa (Review) S3: 7, 13
haematological toxicities (Review) S3: 7
in mantle cell lymphoma (Short report) 401
in metastatic breast cancer 957
in multimodality treatment (Clinical case) 691
in non-small-cell lung cancer 57
in PPNET (Clinical case) 691
in small-cell lung cancer 49
in soft-tissue sarcomas (Short report) 1159
in solid tumors 951
use after epoetin alfa (Review) S3: 13
high-dose ifosfamide
combined with radiotherapy (Short report) 911
for patients with brain metastasis (Short report) 911
for patients with lung cancer (Short report) 911
high-dose melphalan
for patients with multiple myeloma 243
high-dose methotrexate
for patients with non-metastatic osteosarcoma of the extremity 763
high-dose therapy
combined with autologous progenitor cell transplantation 785
for patients with breast cancer S3: 3
for patients with Hodgkin's disease 785
high-grade non-Hodgkin's lymphoma
treatment with CHVmP S1: 67
high- *versus* low-dose levo-leucovorin
for patients with advanced colorectal cancer 169
histology
of peripheral T-cell lymphoma-cases 583
histopathological findings
to document plasma cell tumors (Clinical case) 791
hit-and-run mechanism
of EBV in lymphomagenesis S2: 131
HIV
relation with Kaposi's sarcoma 871
relation with primary central nervous system lymphoma 491
HL-60
implications for Burkitt's lymphoma S1: 25
overexpressing c-*myc* S1: 25
Hodgkin's disease
B-cell development S2: 79
CD30-ligand and CD40-ligand expression S2: 97
chemosensitive relapse 785
classification S2: 3, 11
complications of therapy S1: 115
detection of t(2;5)(p23;q35) S2: 65
excess mortality S1: 115
neurological complications (Clinical case) 593
NPM/ALK fusion mRNA expression S2: 83
occurrence of long-term pulmonary sequelae S1: 19
pathobiology S2: 89
role of eosinophils S2: 89
treatment of children S1: 15, 19
treatment with
BEACOPP (Rapid publication) 143
high-dose therapy combined with ABMT 785
interferon-α-2b (Letter to the editor) 405
melphalan salvage therapy (Short report) 1277
MOPP-ABV chemotherapy and additional radiotherapy S1: 111
PACE BOM chemotherapy 259
treatment without radiotherapy S1: 15
use of fluorescent *in situ* hybridization S2: 65
human herpesvirus-8
discovered in an AIDS-related Kaposi's sarcoma S2: 123
hyperammonaemia
in patients with multiple myeloma (Letter to the editor) 811
hypercalcemia
of malignancy (Short report) 915
treatment with subcutaneous clodronate (Short report) 915
hypersensitivity
paclitaxel-related (Short report) 611
hypodermoclysis
efficacy in hypercalcemia of malignancy and local toxicity (Short report) 915

I

ideal weight
  as a parameter to predict carboplatin clearance (Short report) 607
  of patients (Short report) 607
ifosfamides
  continuous infusion (Short report) 1159
  in advanced epithelial ovarian cancer (Short report) 195
  in germ cell tumors 1229
  in soft-tissue sarcomas (Short report) 1159
  metabolizing oxazaphosphorines 1139
Ig gene rearrangement
  role in the transition from a pre-B cell to a mature B cell S2: 79
IL-2 secretion
  as a prognostic factor for survival 457
  in patients with small-cell lung cancer 457
immune response
  in aggresive non-Hodgkin's lymphoma S1: 43
immunoglobulin light chains
  in patients with non-Hodgkin's disease 267
immunohistochemistry
  of growth factors in human gliomas 1023
  of peripheral T-cell lymphoma-cases 583
  of primary gastric non-Hodgkin's lymphoma S2: 33
  of pyothorax-associated lymphoma 1133
immunophenotype
  role in defining lymphomas S2: 11, 101
immunotherapy
  by EBV-specific cytotoxic T lymphocytes S2: 137
  for patients with non-Hodgkin's lymphoma S1: 133
  versus bone marrow transplantation S1: 133
immunotoxins
  role in leukemia and lymphoma S1: 139
incidence
  of Kaposi's sarcoma as a presentation of AIDS 871
independent radiological review
  during a topotecan trial in ovarian cancer 463
index
  for aggresive lymphomas S1: 43, 49
India
  pediatric non-Hodgkin's lymphoma 893
Indium-111 labeled CYT-103 immunoscintigraphy
  detecting occult gastric carcinoma (Letter to the editor) 301
information
  cancer patients' preferences 857
information revolution (Editorial) 821
infusion
  versus bolus chemotherapy (Review) 15
inguinal metastases
  conservative treatment 1089
  prognostic factors 1089
intensive pediatric treatment
  for patients with Burkitt's lymphoma S1: 77
  pediatric *versus* adult patients S1: 77
interferon
  as a modulator of fluoropyrimidines (Arena) 139
  for patients with colorectal cancer (Arena) 139
interferon-α therapy
  for patients with renal cell carcinoma 71
  prediction of outcome by CD4/CD8 ratio 71
interferon-α-2b
  for patients with Hodgkin's disease (Letter to the editor) 405
interleukin-4
  for patients with AIDS-related Kaposi's sarcoma 79
intermediate non-Hodgkin's lymphoma
  treatment with CHVmP S1: 67
interstitial pneumonitis
  after treatment with docetaxel (Clinical case) 191
intraperitoneal chemotherapy
  for patients with ovarian cancer 1235
  for patients with peritoneal mesothelioma (Short report) 801
intrapleural combination
  followed by carboplatin/cisplation pharmacokinetics 385
  for patients with malignant pleural effusion 385
invasion
  suppression of melanoma cells by antisense DNA 1257
involvement
  cancer patients' preferences 857
irinotecan
  clinical evaluations (Review) 837
  for patients with non-Hodgkin's lymphoma S1: 119
isoflavones
  anticancer properties (Special article) 223

J

JM216
  for patients with non-small-cell lung cancer (Short report) 604

K

Kaposi's sarcoma
  relation with AIDS 871, S2: 123
  role of human herpesvirus-8 S2: 123
Kaposi's sarcoma-associated herpesvirus
  in Kaposi's sarcoma and malignant lymphomas S2: 123
karyotype
  as a prognostic factor for aggresive non-Hodgkin's disease S1: 43
Ki-1 large-cell lymphoma
  characterization by anti-ALK antibody S1: 37
  detection of t(2;5)(p23;q35) S2: 65
  in children S1: 37
  use of fluorescent *in situ* hybridization S2: 65

L

lactic dehydrogenase
  as a prognostic factor for survival 765
lanreotide
  for patients with advanced neuroendocrine gastrointestinal tumors (Short report) 1041
large-cell lymphoma
  CHOP as standard therapy S1: 61, 63
  impact of high-dose salvage therapy (BEAM) S1: 63
  overall survival S1: 63
  poor prognosis S1: 61
L-asparagine-depletion
  pharmacodynamics (Letter to the editor) 204
late effects
  of treatment in children with Hodgkin's disease S1: 15, 19

late relapse
of germ cell tumors 41
left ventricular function
decreasing after treatment with 5-fluorouracil and folinic acid (Short report) 705
leucovorin
combined with cisplatin (Letter to the editor) 713
combined with 5-fluorouracil (Letter to the editor) 713
for patients with head and neck cancer (Letter to the editor) 713
leukemia
acute myelocytic in adults 251
event-free survival S1: 77
pediatric *versus* adult patients S1: 77
role of *bcl*-6 expression S2: 101
leukocytes
cisplatin accumulation 1145
Lhermitte's sign
in patients treated with docetaxel 187
limiting dilutions
as a method for establishing quantitative PCR assay (Rapid publication) 633
linear analogue self-assessment (LASA) scales
as an indicator for quality of life assessment (Special article) 825
liver metastases
from colorectal cancer (Clinical case) 393
liver surgery
for gastrointestinal tumors (Review) 317
in elderly patients (Review) 317
l-leucovorin
as a modulator of 5-fluorouracil 169
combined with epirubicin and 5-fluorouracil (Short report) 797
for patients with advanced colorectal cancer 169
for patients with advanced pancreatic cancer (Short report) 797
lobaplatin
for patients with advanced urothelial tract tumors (Short report) 695
local recurrence
of breast cancer 235
risk factors 235
logistic regression
in CB/CC diffuse lymphomas S2: 25
long-range PCR
detecting t(2;5)(p23;q35) in anaplastic large-cell lymphoma S2: 59
long-term survival
of patients with non-Hodgkin's lymphoma S1: 71
of patients with small-cell lung cancer 1009
low-grade lymphomas
usefulness of the international index S1: 49
low-grade MALT lymphomas
therapeutic features of patients 883
treatment with α-interferon 883
lung cancer (Commentary) 27
coagulation 781
complete spontaneous remission (Clinical case) 1031
prognosis 781
pulmonary toxicity (Clinical case) 191
treatment with
chemo-radiotherapy (Short report) 911
chemotherapy (Clinical case) 285
docetaxel (Clinical case) 191
JM216 (Short report) 604
paclitaxel and oral etoposide 485
lung function
complications in children with Hodgkin's disease S1: 19
lymphadenopathy
in patients with non-Hodgkin's disease 267
lymphoblastic lymphoma
in India 893
treatment with chemotherapy 893
lymphocyte biology S1: 83
lymphocyte subsets
in patients with renal cell carcinoma 71
lymphomagenesis
correlation with trans-rearrangements S2: 45
lymphoma transformation
caused by translocated *bcl*-2 genes S2: 119
lymphomas
classification S2: 3, 11
diagnosis of residual mass S1: 57
in children S1: 7
new drugs S1: 119
positron emission tomography S1: 57
prognostic value of the international index S1: 49
role of *bcl*-6 expression S2: 101
treatment with
Helicobacter pylori S2: 37
intensive chemotherapy and autologous transplant (Short report) 701
paclitaxel S1: 129
12-week combination chemotherapy 1125
lymphoproliferative disorders
induced by EBV S2: 137
Lynch syndrome
recent discoveries (Clinical case) 1151

M

MACOP-B
advantage over CHOP therapy in non-Hodgkin's lymphoma S1: 71
long-term survival S1: 71
MAGE
in patients with breast cancer 369
magnesium depletion
caused by cisplatin infusion (Clinical case) 1263
magnetic resonance
staging patients with mediastinal Hodgkin's disease S1: 53
major subtypes
of primary B-cell lymphomas of the skin S2: 29
malignant fibrous histiocytoma
of bone 1107
compared to osteosarcoma 1107
treated with neoadjuvant chemotherapy 1107
malignant lymphoma
overview S1: 1, 6
relation with tuberculous infection 1133
role of hepatitis B virus carriers S1: 107
malignant portal hypertension
transjugular stent implantation (Short report) 200
MALT lymphoma

definition (Review) 727
evolving malignant lymphomas S2: 33
t(11;18) translocation 979
treatment with *Helicobacter pylori* S2: 37
mantle cell lymphoma
genetic abnormalities S2: 109
role of *bcl*-1 S2: 109
treatment with high-dose therapy and autologous stem cell transplantation (Short report) 401, (Short report) 701
treatment with VAD regimen, HDT and PBSCT S1: 103
margins
as a factor relating to the development of local recurrences 899
surgical 899
measurable diseases
by independent radiological review 463
ovarian cancer 463
mediastinal Hodgkin's disease
detection techniques S1: 53
mediastinum
non-seminomatous germ cell tumors 555
megestrol acetate
for patients with endocrine-insensitive advanced cancer 277
improving quality of life 277
megestrol activity
in recurrent adult type granulosa cell tumor of the ovary (Letter to the editor) 811
melanoma
risk increase when using psoralens (Arena) 435
treatment with antisense DNA 1257
treatment with tirapazamine combined with cisplatin 363
melphalan therapy
for patients with Hodgkin's disease (Short report) 1277
menstrual cycle
and timing of breast surgery 751
mesothelioma
treatment with intraperitoneal suramin (Short report) 801
meta-analysis
of treatment of hepatocellular carcinoma (Review) 117
metastasectomy
combined with chemotherapy 765
survival rate 765
metastatic breast cancer
dose intensity (Editorial) 109, 155, (Review) S3: 3
treatment with adjuvant therapy S3: 3
treatment with circadian-timed paclitaxel and cisplatin therapy 663
treatment with epirubicin 155
metastatic non-seminomatous testicular cancer
postchemotherapy resections 531
metastatic renal cell carcinoma
treatment with interferon-α therapy 71
methotrexate
modulation of 5-fluorouracil (Short report) 917
for patients with advanced pancreatic cancer (Short report) 917
methoxymorpholinodoxorubicin
recommended dosage (Short report) 807
methylprednisolone
combined with ondansetron, cisplatin and metopizamine 887
metopizamine
combined with methylprednisolone, ondansetron and cisplatin 887
micromanipulation
of Hodgkin's cells S2: 79
of Reed–Sternberg cells S2: 79
minimal residual disease
as a cause for relapses S1: 139
by qualitative methods (Rapid publication) 633
definition (Rapid publication) 633
mitomycin
combined with molgramostim (Arena) 637
for patients with advanced sarcomas (Arena) 637
mitomycin C
for patients with advanced colorectal cancer 995
for patients with advanced gastric cancer (Short report) 294
mitotane
for patients with adrenocortical carcinoma (Review) 423
mitoxantrone
combined with fludarabine 379
for patients with non-Hodgkin's disease 379
moderately emetogenic chemotherapy
causing delayed emesis 561
modified MIC
for patients with advanced non-small-cell lung cancer (Short report) 709
nephrotoxicity (Short report) 709
molecular biology (Commentary) 27
of pyothorax-associated lymphoma 1133
molgramostim
combined with cytotoxic drugs (Arena) 637
for patients with advanced sarcomas (Arena) 637
monoclonal antibodies
treatment of leukemia and lymphoma S1: 139, S2: 101, S2: 101
treatment of non-Hodgkin's lymphoma S1: 133
mortality
as a complication of Hodgkin's disease therapy S1: 115
mucosa-associated lymphoid tissue
infection with *Helicobacter pylori* S2: 37, 41
multicentric Castleman's disease
role of human herpesvirus-8 S2: 123
multidrug resistance protein (MRP)
overexpression by human tumor xenografts 1221
treatment with docetaxel and paclitaxel 1221
multiple myeloma
compared with plasmacytomas (Clinical case) 791
detection of malignant cells (Rapid publication) 633
severe hyperammonaemia (Letter to the editor) 811
treatment with bone marrow and peripheral blood stem cell transplantation (Editorial) 219
treatment with peripheral blood progenitor cell transplantation 243
using qPCR assay for the detection of malignant cells (Rapid publication) 633
myelodysplasia
relation with pulmonary infiltration (Clinical case) 905

N

nasopharyngeal cancer
treatment with paclitaxel and carboplatin 451
treatment with zorubicin *versus* zorubicin/cisplatin 739
neoadjuvant chemotherapy

combined with surgery 765
in malignant fibrous histiocytoma of bone 1107
in non-metastatic osteosarcoma of the extremity 765
in osteosarcoma 1107
post-relapse survival 765
neoadjuvant therapy
for patients with head and neck cancer (Letter to the editor) 713
nephrotoxicity
in patients treated with modified MIC (Short report) 709
neuroendocrine tumors
treatment with high-dose lanreotide (Short report) 1041
neurological complications
of Hodgkin's disease (Clinical case) 593
neuropathy
in patients treated with docetaxel 187
neurotoxicity
in patients treated with a combination of carboplatin and paclitaxel 355
neutropenia
effects of treatment schedules of Filgrastim 1117
neutropenic enterocolitis
in patients with breast cancer (Letter to the editor) 405
neutrophilia
relation with pulmonary infiltration (Clinical case) 905
non-gastrointestinal lymphoid tissue
features of patients 833
treatment with α-interferon 883
non-Hodgkin's lymphoma
advantage of MACOP-B over CHOP S1: 71
amyloid deposition 267
changing incidence S2: 49
characterization by anti-ALK antibody S1: 37
classification S2: 3, 49
cyclin-dependent kinase inhibitors S2: 71
difference with CB/CC diffuse lymphomas S2: 25
in children 893, S1: 37
in India 893
in the elderly 973
long-term survival S1: 71
primary lymphoma of the stomach S1: 85
radioimmunotherapy (Arena) 133
treatment with
chemotherapy (Short report) 497, 893
CHVmP S1: 67
fludarabine and mitoxantrone 379
VAD regimen, HDT and PBSCT S1: 103
non-metastatic osteosarcoma of the extremity
post-relapse survival 765
surgery 765
treatment with neoadjuvant chemotherapy 765
non-opioid-responsive pain
treatment with TTs fentanyl (Review) S3: 21
non-seminomatous teratoma
treatment with cyclical POMB/ACE chemotherapy 477
non-small-cell lung cancer
nephrotoxicity (Short report) 709
treatments (Editorial) 513
treatment with
carboplatin and paclitaxel (Short report) 697
cisplatin and etoposide 525
cisplatin and tirapazamine (Short report) 1269
cisplatin, gemcitabine and vinorelbine (Short report) 1045
combination chemotherapy (Short report) 709
JM216 (Short report) 604
modified MIC (Short report) 709
single-agent gemcitabine 525
VIP-E therapy 57
NPM/ALK
in Hodgkin's and Reed–Sternberg cells S2: 83
nude mice
bearing human tumor xenografts 1221
testing antitumor efficacy 1221

O

obesity
as a problem for predicting carboplatin clearance 607
objective response rate
during a topotecan trial in ovarian cancer 463
in a independent radiological review 463
occult gastric carcinoma
detection with Indium-111 labeled CYT-103 immunoscintigraphy (Letter to the editor) 301
oncogenes
role of *bcl*-6 gene in AIDS-related lymphomas S2: 101
role of *bcl*-6 protein expression in lymphoid tissues S2: 101
oncology
review articles (Special article) 1185
oncology education
in the Balkans and Middle East (Letter to the editor) 1281
ondansetron
combined with methylprednisolone, metopimazine and cisplatin 887
ophthalmic toxicity
following paclitaxel infusion (Letter to the editor) 1053
opioid rotation
as a strategy for pain control (Review) S3: 21
opioids
for patients with cancer pain (Review) S3: 15, 21, 25
oral chemotherapy
for patients with non-small-cell lung cancer (Short report) 604
oral etoposide
for patients with advanced gastric cancer (Short report) 294
oral ondansetron
recurrent bowel occlusion (Letter to the editor) 919
osteosarcoma
compared to malignant fibrous histiocytoma 1107
risk factors for local recurrences 899
treatment with neoadjuvant chemotherapy 1107
outcome analysis
of postchemotherapy resections of metastatic testicular cancer 531
outcome research
on clinical decision making (Arena) 1207
on quality of life assessment (Arena) 1207
ovarian cancer
dose intensity 327
drug resistance markers (Editorial) 314
glutathione S-transferase activity 343
independent radiological review 463

Ki-67 (MIB1) labeling index as a prognostic factor 469
long-term survival 643
megestrol activity (Letter to the editor) 811
predictive factors 963
prognostic factors (Editorial) 937
response to chemotherapy 343, 963
role of second-look laparotomy 643
salvage therapy (Editorial) 937
survival factors 469
topotecan trial 463
treatment with
carboplatin and paclitaxel 351, 355
cisplatin/carboplatin 327
ifosfamide and paclitaxel salvage chemotherapy (Short report) 195
platinum 963

P

paclitaxel
antitumor activity (Editorial) 1183
antitumor efficacy 1221
combined with
anthracyclines (Review) 939
carboplatin 351, 355, 451, (Short report) 697
cisplatin 663, 1157
cisplatin and epirubicin 969
cyclophosphamide 655
docetaxel 1221
compared to docetaxel (Editorial) 1183
in advanced breast cancer 655, (Review) 939
in advanced epithelial ovarian cancer (Short report) 195, 355
in advanced ovarian cancer (Short report) 803
in advanced solid tumors (Short report) 291
in germ cell tumors 1229
in head and neck cancer 451, (Short report) 1157
in lymphomas S1: 129
in metastatic breast cancer 663
in non-Hodgkin's lymphoma S1: 119
in non-small-cell lung cancer (Short report) 697
in ovarian cancer 351
in uterine carcinoma 969
for the treatment of cisplatin accumulation in leukocytes 1145
hypersensitivity reactions (Short report) 611
paclitaxel infusion
followed by ophthalmic toxicity (Letter to the editor) 1053
palliation
in patients with gastric cancer 163
palliative therapy
for patients with advanced pancreatic cancer (Short report) 797
for patients with esophaegeal cancer (Short report) 198
pamidronate
for patients with metastatic bone disease 1243
pancreatic cancer
treatment with
epirubicin, 5-fluorouracil and l-leucovorin (Short report) 797
5-fluorouracil modulated by PALA and MTX (Short report) 917
protracted infusional 5-fluorouracil and carboplatin 439
paraneoplastic temporal lobe epilepsy
anti-Yo autoantibody (Letter to the editor) 919
pathogenesis
of Burkitt's lymphoma 987
pathology
classification of lymphomas S2: 3
patient assessment
for the definition of pain (Review) S3: 21
patient expectation
of the doctor 877
PCR methods
detecting t(2;5)(p23;q35) in anaplastic large-cell lymphomas S2: 65
detecting translocations in childhood Burkitt's lymphoma S1: 31
penile carcinoma
prognostic factors 1089
treatment with brachytherapy 1089
perforin
role in CTL-mediated lysis S2: 75
peripheral blood progenitor cell support
in patients with chronic myeloid leukaemia (Clinical case) 91
peripheral blood progenitor cell transplantation
in mantle cell lymphoma (Short report) 401
in multiple myeloma 243
peripheral blood stem cell transplantation
in combination with bone marrow transplantation (Editorial) 219
in multiple myeloma (Editorial) 219
in non-small-cell lung cancer 57
in small-cell lung cancer 49
peripheral stem cell transplantation
combined with intensive therapy (Short report) 701
for patients with mantle cell lymphoma (Short report) 701
peripheral T-cell lymphoma
clinico-pathological study of cases 583
REAL classification 583
perlecan
role as a regulator of growth factor activity 1257
p15/MTS2
as a prognostic factor for mantle-cell lymphoma S2: 71
p53
as a prognostic factor for mantle-cell lymphoma S2: 71
as a prognostic factor for survival of ovarian cancer patients 469
mutations in Burkitt's lymphoma 987
PGP
correlation with clinical and prognostic characteristics 335
predicting response to therapy in breast cancer 335
pharmacokinetics
carboplatin clearance (Short report) 607
carboplatin combined with cisplatin 385
for obese patients (Short report) 607
for patients with malignant pleural effusion 385
phase I study
of alpha-tocopherol effects on 13-cis-retinoic acid toxicity 85
of cisplatin, gemcitabine and vinorelbine for non-small-cell lung cancer (Short report) 1045
of methoxymorpholinodoxorubicin dosage (Short report) 807
of paclitaxel and oral etoposide for lung cancer 485
phase II study
of high-dose radiation therapy combined with chemotherapy for anal canal cancer 575
of PACE BOM chemotherapy for Hodgkin's disease 259

of single-agent gemcitabine *versus* cisplatin–etoposide for non-small-cell lung cancer 525
of the combination AZT, 5-fluorouracil and leucovorin for metastatic colorectal cancer 539
of the combination carboplatin and paclitaxel for ovarian cancer 351
phosphonacetyl-L-aspartate
combined with 5-fluorouracil and methotrexate (Short report) 917
for patients with advanced pancreatic cancer (Short report) 917
phosphorothiotate
antisense oligodeoxynucleotides S1: 25
implications for Burkitt's disease S1: 25
physical performance
correlation with cancer fatigue 1251
physician–patient communication
patient expectations 877
platelet-derived endothelial cell growth factor
and adjuvant CMF therapy 271
for patients with breast cancer 271
randomised 525
platinum
for patients with non-small-cell lung cancer (Short report) 604
for patients with ovarian cancer 569
platinum salts
for patients with non-small-cell lung cancer 1003
pleuritis
relation with malignant lymphomas 1133
pneumothorax
relation with malignant lymphomas 1133
population-based registries
for the incidence of non-Hodgkin's lymphoma S2: 49
portal vein stent
implantation in cancer patients (Short report) 200
obstruction in cancer patients (Short report) 200
positron emission tomography
for diagnosis of endocrine pancreatic tumors (Short report) 1041
for diagnosis of residual mass in patients with lymphoma S1: 57
postchemotherapy
for patients with metastatic non-seminomatous testicular cancer 531
post-HDCT chemotherapy
for patients with germ cell tumors 1229
postremission consolidation therapy
for patients with acute myeloid leukemia 251
PPNET
treatment with multimodality therapy (Clinical case) 691
prediction
thymidine phosphorylase for patients with breast cancer 271
predictive factors
for patients with ovarian cancer 963
predictive factors for histological findings
for patients who underwent postchemotherapy resections 531
for patients with non-seminomatous testicular cancer 531
preferences
of cancer patients 857
premenopausal node-positive breast cancer
timing of breast surgery 751
primary central nervous system lymphoma
in immunocompetent patients (Review) 227
in relation with HIV 491
treatment with combined therapy (Review) 227
primary cutaneous B-cell lymphomas
diagnosis S2: 29
treatment S2: 29
primary gastric lymphoma
detection of bacterial flora S2: 33
primary prevention
by genetic screening (Arena) 945
primitive neuroectodermal tumors
treatment with pediatric chemotherapy 1099
progenitor cell mobilisation
clinical application of epoetin alfa (Review) S3: 7
prognosis
for patients pretreated with drug resistance parameters 335
for patients treated with interferon-α therapy 71
in aggresive non-Hodgkin's lymphoma S1: 43
in breast cancer 335
in epithelial ovarian cancer 343
in Kaposi's sarcoma as a presentation of AIDS 871
in lung cancer 781
in ovarian cancer 643
in renal cell carcinoma 71
role of second-look laparotomy 643
prognostic factors
in carcinoid tumor 685
in chemosensitive relapsed Hodgkin's disease 785
in head and neck cancer 773
in low-grade lymphomas S1: 49
in penile carcinoma 1089
in small-cell lung cancer 457, 1009
interleukin-2 secretion 457
usefulness of the international index S1: 49
prognostic groups
of patients with small-cell-lung cancer 547
prognostic index
for survival in small-cell lung cancer 547
including LDH, hypoalbuminemia, neutrophilia, disease extent and PS 547
validation 547
progressive multifocal leukoencephalopathy
due to Hodgkin's disease (Clinical case) 593
proliferative fraction
in ovarian carcinomas 469
prognostic implications for survival 469
protracted venous infusion
for patients with gastrointestinal cancers (Special article) 111
p16/MTS1
as a prognostic factor for mantle-cell lymphoma S2: 71
psoralens
increased melanoma risk (Arena) 435
psychological distress
correlation with physical performance and cancer fatigue 1251
pulmonary infiltration
associated with myelodysplasia (Clinical case) 905
PVI 5-FU
combined with mitomycin C 995
for patients with advanced colorectal cancer 995
pyothorax

associated lymphoma 1133
pyridinium cross-links
role in metastatic bone disease 1243

Q

11q13
role in malignant lymphomas S2: 109
quality of life
clinical decision making (Arena) 1207
of patients with breast cancer (Special article) 825
of patients with endocrine-insensitive advanced cancer 277
treatment with megestrol acetate 277
quality of sex life
impact on patients with breast cancer 149
quantitative PCR
as a method for the detection of malignant cells (Rapid publication) 633

R

radiation therapy
following breast conservation surgery (Editorial) 217
for patients with anal canal cancer 575
in combination with chemotherapy 575
radioimmunotherapy
for patients with non-Hodgkin's lymphoma S1: 133
radiotherapy
combined with cisplatin and fluorouracil 773
combined with MOPP-ABV chemotherapy S1: 111
in advanced Hodgkin's disease 259, S1: 111
in head and neck cancer 773
in MALT lymphomas 883
in primary central nervous system lymphoma (Review) 227
in seminoma 37
use of $5HT_3$ antagonists 302
Raji
implications for Burkitt's lymphoma S1: 25
overexpressing *c-myc* S1: 25
raltitrexed
for patients with hepatocellular carcinoma (Short report) 500
randomized controlled trials
of adjuvant therapy for breast cancer (Special article) 825
of a treatment for patients with advanced gastric cancer 163
of a treatment for patients with hepatocellular carcinoma (Review) 117
of MACOP-B over CHOP therapy in non-Hodgkin's lymphoma S1: 71
of postoperative radiotherapy for breast cancer 757
of treatment with high-dose *versus* standard-dose cytarabine 251
of various treatment schedules of Filgrastim on hematologic recovery 1117
REAL
classification for non-Hodgkin's lymphoma S2: 49
recurrences
after limb-salvage surgery 899
recurrent bowel occlusion
with oral ondansetron (Letter to the editor) 919
red blood cell transfusion
as a treatment for haematological toxicities (Review) S3: 7
Reed–Sternberg cell
micromanipulation S2: 79
role of eosinophils S2: 89
refractory lymphoma
treatment with autologous bone marrow transplantation 675
treatment with salvage therapy with mini-BEAM and BMT 675
relapsed lymphoma
after treatment with 12-week combination chemotherapy 1125
treatment with autologous bone marrow transplantation 675
treatment with salvage therapy with mini-BEAM and BMT 675
residual masses
diagnosis by PET S1: 57
from metastatic non-seminomatous testicular cancer 531
in patients with lymphoma S1: 57
resources
implications for cancer centres 669
morbidity in patients by CTD 669
therapy of cancer pain (Review) S3: 15
response to chemotherapy
of patients with
advanced pancreatic carcinoma 439
epithelial ovarian cancer 343
non-Hodgkin's disease 379
ovarian cancer 963
seminoma 37
role of glutathione S-transferase 343
retinoids
acid toxicity 85
alpha-tocopherol effects 85
review
of the role of *bcl-1*/cyclin D1 in malignant lymphomas S2: 109
of the role of immunotoxins in leukemia and lymphoma S1: 139
review articles
use of systematic methods (Special article) 1185
risk factors
for breast cancer after diagnosis of fibroadenoma (Short report) 297
for local recurrence in breast cancer 235

S

salvage therapy
for patients with ovarian cancer (Editorial) 937
prognostic factors (Editorial) 937
sarcomas
treatment with cytotoxic drugs and molgramostim (Arena) 637
satisfaction
of patients with the consultation 877
secondary surgical intervention
for patients with metastatic non-seminomatous testicular cancer 531
secondary tumors
cause of mortality S1: 115
occurring in children with Hodgkin's disease S1: 15
second-line chemotherapy
for patients with colorectal cancer (Short report) 1163
for patients with ovarian cancer 963
second-look laparotomy
on patients with ovarian cancer 643
role in long-term survival 643
second-look surgery
on patients with advanced epithelial ovarian cancer (Editorial) 627
secretions
management by glycopyrrolate (Short report) 198

treatment of esophageal cancer patients (Short report) 198
seminoma
treatment with cisplatin based chemotherapy 37
sequential chemotherapy
for patients with solid tumors 951
severe combined immune deficiency mice
treatment with adoptive chemotherapy of EBV-induced lymphoproliferations S2: 137
sexual functioning
after breast cancer (Editorial) 105, 149, (Letter to the editor) 616
side effects
of cisplatin infusion (Clinical case) 1263
signalling
role of epidermal growth factor receptor (Review) 1197
single-cell PCR
detecting rearranged V genes S2: 79
detecting NPM/ALK fusion mRNA expression S2: 83
skin
extranodal non-Hodgkin's lymphomas (Review) 727
malignant lymphoma S1: 83
small-cell lung cancer
IL-2 secretion as prognostic factor 457
indices for survival 547
long-term survival 1009
prognostic factors 547
responding to chemotherapy (Letter to the editor) 503
survival 457, 1009
treatment with VIP-E therapy 49
small non-cleaved cell lymphoma
in children 893
in India 893
treatment with chemotherapy 893
SN-38
relation with CPT-11 toxicity (Short report) 1049
soft-tissue sarcomas
treatment with continuous-infusion ifosfamide (Short report) 1157
solid tumors
treatment with
hematopoietic progenitor-cell support 951
high-dose chemotherapy 951
retinoids 85
solitary plasmacytoma
compared to other meningeal tumors (Clinical case) 791
problems with radiological diagnosis (Clinical case) 791
somatic mutation
of translocated *bcl*-2 genes S2: 119
role in morphological transformation of follicular lymphomas S2: 119
soybean
anticancer properties (Special article) 223
specific immunotherapy
for patients with breast cancer 369
spontaneous remission
in a patient with metastatic non-small-cell lung cancer (Clinical case) 1031
sputum
difficulties in patients with esophageal cancer (Short report) 198
management by glycopyrrolate (Short report) 198
squamous cells
as prognostic factors 1089
carcinoma of the penis 1089
SR 4233
combined with cisplatin (Short report) 1269
for patients with advanced non-small-cell lung cancer (Short report) 1269
stability
of cancer patients' preferences 857
standard protocols
for independent reviews 463
stem cell transplantation
for patients with PPNET (Clinical case) 691
stochastic model
for the treatment of breast cancer (Arena) 1075
stomach lymphoma
histological features, sites of involvement and management S1: 85
strand breaks
of AZT-induced DNA 539
sublingual nitrate
helpful for patients with food problems (Letter to the editor) 1053
support
for cancer patients' preferences 857
supportive care
for patients with cancer pain (Review) S3: 15
suramin
for patients with non-Hodgkin's lymphoma S1: 119
for patients with peritoneal mesothelioma (Short report) 801
surgery
on patients with
gastric lymphomas (Editorial) 419
germ cell tumors 41
high-grade osteosarcoma of the extremities 899
premenopausal node-positive breast cancer 751
recurrences 899
timing 751
surgery signals
for micrometastatic growth (Arena) 1075
surgical approach
to colorectal cancer (Clinical case) 393
surgical oncology
on elderly patients (Review) 317
survival
IL-2 secretion as a prognostic factor 457
impact of high-dose salvage therapy (BEAM) S1: 63
indices 547
of patients treated with protracted infusional 5-fluorouracil and carboplatin 439
of patients with
advanced large-cell lymphomas S1: 63
advanced pancreatic carcinoma 439
carcinoid tumors 685
Kaposi's sarcoma as a presentation of AIDS 871
ovarian cancer 643, 1235
penis carcinoma 1089
small-cell lung cancer 457, 547
prognostic factors 547, 685
role of second-look laparotomy 643
symptom control
by means of chemotherapy 445

in recurrent cell squamous cell carcinoma of the head and neck 445
systematic methodology
in review articles (Special article) 1185
Sweet's syndrome
associated with pulmonary infiltration (Short report) 905

T
targeted therapy
for pediatric lymphomas S1: 7
taxotere
inducement of peripheral neuropathy 187
T cell
role in tumor development S1: 83
T-cell lymphomas
classification S2: 17
t(11;14)
in malignant lymphomas S2: 109
t(11;18) translocation
in MALT lymphomas 979
telomerase
biology (Review) 1063
preclinical and clinical strategies (Review) 1063
telomeres
biology (Review) 1063
preclinical and clinical strategies (Review) 1063
t(14;18)
as a marker for cure of follicular lymphoma S1: 89
therapeutics-oncology
dosage of methoxymorpholinodoxorubicin (Short report) 807
toxicity (Short report) 807
thrombin-antithrombin complex
as a prognostic factor for coagulation in lung cancer 781
thromboembolism
relation with cancer 669
cause of morbidity 669
thymidine phosphorylase
and adjuvant CMF therapy 271
for patients with breast cancer 271
tirapazamine
combined with cisplatin 363, (Special article) 1269
for patients with advanced malignant melanoma 363
for patients with advanced non-small-cell lung cancer (Short report) 1269
TNF-like ligands
role of eosinophils S2: 89
tobacco control
European Cancer Experts recommendations (Special article) 9
tobacco smoking
European Cancer Experts recommendations (Special article) 9
in Central and Eastern Europe (Commentary) 137
relation to cancer (Commentary) 137
Tomudex
for patients with hepatocellular carcinoma (Short report) 500
T1-201 SPECT
in primary central nervous system lymphoma 491
topoisomerase I inhibitors
clinical evaluation (Review) 837
topotecan
clinical evaluation (Review) 837
combined with cisplatin 1003
for patients with non-Hodgkin's lymphoma S1: 119
for patients with non-small-cell lung cancer 1003
total body irradiation
and high-dose therapy 243
for patients with multiple myeloma 243
toxicity
in patients treated with
a combination of glutathione and cisplatin 569
a combination of protracted 5-fluorouracil and carboplatin 439
a combination of topotecan and cisplatin 569
pediatric chemotherapy protocols 1099
in post-remission therapy 251
TTS fentanyl
for patients with non-opioid-responsive pain (Review) (Editorial) S3: 21
transitional cell carcinoma
treatment with lobaplatin (Short report) 695
transjugular intrahepatic portosystemic stent-shunt procedure (TIPS)
in patients with malignant vein obstruction (Short report) 200
translocations
detecting by PCR methods S1: 31
in childhood Burkitt's lymphoma S1: 31
transplantation
for patients with lymphoid malignancies (Review) 515
trans-rearrangements
increased risk of lymphoid malignancy S2: 45
treatment
of children with lymphomas S1: 7
of children with non-Hodgkin's lymphoma 893
of patients with hepatocellular carcinoma (Review) 117
of patients with primary B-cell lymphomas of the skin S2: 29
of patients with small-cell lung cancer 1009
treatment outcome
of patients treated with raltitrexed (Short report) 500
of patients with hepatocellular carcinoma (Short report) 500
treatment package
for patients with cancer pain (Review) S3: 15
treatment toxicity and mortality
after VIP-E treatment 49, 57
of patients with non-small-cell lung cancer 57
of patients with small-cell lung cancer 49
trisomy 12
detection by CD34+ progenitor cells S2: 55
in a patient with B-cell chronic lymphocytic leukemia S2: 55
t(2;5)(p23;q35)
detected by amplification of genomic DNA S2: 59
in anaplastic large-cell lymphoma S2: 59
tuberculosis
relation with malignant lymphomas 1133
tumor dormancy
hypothesis (Arena) 1075
tumor growth
failing as model (Arena) 1075
tumor lysis syndrome (Letter to the editor) 97
tumor necrosis
in patients treated with neoadjuvant chemotherapy 765
in patients with non-metastatic osteosarcoma of the extremity 765
tyrosine kinase

role of epidermal growth factor receptor (Review) 1197
role in breast cancer (Special article) 223
role in cancer therapy (Commentary) 429

U
506U
for patients with non-Hodgkin's lymphoma S1: 119
UCNT
role of chemotherapy (Editorial) 723
treatment with zorubicin *versus* zorubicin–cisplatin 739
U-5HIAA
as a marker for carcinoid tumors 685
reduction by high-dose treatment with lanreotide (Short report) 1041
urothelial cancer
treatment with chemotherapy (FAP) 373
treatment with lobaplatin (Short report) 695
urothelial tract tumors
treatment with lobaplatin (Short report) 695
VAD regimen
for patients with mantle-cell lymphomas S1: 103
V(D)J recombination
mechanism of genetic instability S2: 45
vinorelbine
combined with cisplatin and gemcitabine (Short report) 1045
combined with 5-fluorouracil and folinic acid 865
for patients with breast cancer 865
for patients with non-small-cell lung cancer (Letter to the editor) 714, (Short report) 1045
overdosage (Letter to the editor) 714
viral integration
leading to chromosome instability S2: 131
of Epstein–Barr virus in Burkitt's lymphoma S2: 131
vitamin E
effect on 13-cis-retinoic acid toxicity 85
vorozole
clinical efficacy 745
endocrine activity 745
for patients with postmenopausal breast cancer 745

W
weekly schedule
for cisplatin–paclitaxel treatment in advanced solid tumors 291

Z
zidovudine
for patients with metastatic colorectal cancer 539
in combination with 5-fluorouracil and leucovorin 539
maximum tolerable doses 539
zorubicin
combined with cisplatin 739
for patients with UCNT 739

Annals of Oncology 8: 1305–1314, 1997.

Index of authors Volume 8 (1997)

A

A'Hern RP 445
Aapro MS 302, 317, 865
Aarsman CJM 1015
Abate G 593
Abbasciano V 1263
Abbey ME 1243
Abdi E 277
Achour NR 919
Adatia R 1257
Adde M 893
Adenis A 500
Adler M 143
Advani R 601
Advani S 893
Ahlgren JD 439
Ahmedzai S 821, S3: 21
Akiyoshi T 369
Akrivos T 195
Alberici F 491
Albini A 1257
Aldinucci D S2: 89
Alimena G 175
Allal AS 681
Allegrini G 539
Altermatt H-J 335
Aluigi P 899
Alvarez I S2: 37
Amadori S 175
Amichetti M 649
Amoroso D 745
Anderson L S1: 63
Anderson N 15
Andreeff M S2: 97
Andreoni B 317
Andreoni G 865
Andreopoulou E 697, 1213
Andreuccetti M 539
Angiolini C 117
Angus B S2: 65
Anthoine D 1009
Antimi M 1159
Antonuzzo A 539
Aparicio J 547
Apolone G 1059
Aravantinos G 373
Arbuck SG S1: 119
Archer D 445
Arends JW S2: 33
Arico M S1: 19
Armitage JO 206
Armstrong S 1117
Arnoldi E 169
Ascani S 583, 883, 1133
Assens C 951
Athanassiades A 451, 697, 1213
Athanassiades P 195
Attili A 649
Audisio RA 317
Auer IA 979
Auerbach M 439
Autier P 435
Avvisati G 175, 1273
Ayoub JP S1: 129

B

Bacchi M 251, 335
Bacci G 765, 1170
Bachier C S1: 129
Bacoyiannis C 373, 451
Baez F 247
Bafaloukos D 1213
Bahamonde L 899
Baio A S1: 19
Bajetta E 649, 1207
Baldelli AM 393
Baldeyrou P 191
Ballatori E 615
Balter R S1: 77
Balzarini L S1: 53
Balzarotti M 497
Bamia C 1213
Banki K S1: 37
Barchielli A S2: 49
Bardina A 681
Barni S 149, 169, 616, 649
Barrett D S1: 37
Bartels H 401
Barth S S1: 139
Bartnitzke S S2: 131
Bateman AR 669
Baudin E 423
Bauknecht T 355
Baumgart J 204
Bazarbashi S 663
Bazelly B 714
Bedikian AY 363
Beecken W-D 1167
Begent RHJ 477
Behrendt H S1: 15
Beijnen JH 351, 801
Belge G S2: 131
Bellas C S2: 37
Beller E 277
Benasso M 773
Bendandi M 379, 883
Benedetti Panici P 343
Benelli R 1257
Bénézet S 607
Berard CW S1: 37, S2: 3
Berger DP 200
Berger F 701
Bergh J 101, 235, 757
Bergman B 525
Bernhard J 825
Bernier J 6
Berns T 917
Bernstein I S1: 133
Berry J 663
Bertolini A 705
Bertoni F 422, 727
Betticher DC 1170
Bevilacqua P 469
Beyer W S1: 57
Bhatia K 987
Bhidayasiri R 669
Bibiloni J 899
Bichisao E 649
Bieri S 681
Biganzoli L 1177
Bijnens L S1: 67
Biondi A 247
Birkmann J 1031
Björkholm M 1281
Blijham GH 1015
Boadle D 277
Boardman P 294
Boccardo F 745
Bochtler H 355
Bodenstein H S1: 85
Boehn A 405
Boffetta P 137
Bogliolo G 385
Boixeda D S2: 37
Bokemeyer C 531, 1229
Bolelli GF 649
Bolis GB 463, 1133
Bombardieri E 649, S1: 53
Bonadonna G 497, 1075, S1: 53
Bonardi R 297
Bonelli L 773
Bonfante V S1: 53
Bonoldi E 469
Bookman MA 611
Borel C 919
Bosch F S1: 93
Bossi G S1: 19
Bot FJ S2: 33
Böthig R 1163

Botti G 1045
Bottino GB 385
Bouafia F 701
Boven E 957
Bower M 477
Bowman A 569
Boyer MJ 485, 857
Boyle P 9, 108, 435
Bozzetti F 497
Brach del Prever A 765
Brada SJL 1053
Braeckman J 691
Brambilla E 1009
Bramwell VHC 1185
Brandwein J 675
Braybrooke JP 294
Breach N 445
Breccia M 1273
Breed W S1: 111
Brema F 745
Brensinger JD 1151
Briasoulis E 451, 811, 1213
Briccoli A 765, 899
Brincker H S2: 25, 49
Briskomatis A 583, 1133
Bron D S1: 67
Brouwer E 1145
Brown CB 1277
Brown R 877
Bruera E 915
Brufman G 155
Brugger W 49, 57
Brunetti I 539
Bruzzi P 1207
Bugat R 607
Bulgheroni P 705
Bullerdiek J S2: 131
Bülzebruck H 457
Bumann D S1: 57
Bunn P 27
Burg G S1: 83
Burger CW 1235
Burger, JA 200
Burgers M S1: 111
Burnelli R 583
Burris HA 1003
Büschel G 1031
Buser K 335
Butow PN 857, 877
Buzaid AC 363
Buzby JS S1: 25
Buzzoni R 649

C
Cabanillas F S1: 129, S2: 59, 97
Cairo MS S1: 25
Calleja JL S2: 37
Campanacci 899
Canal P 607
Candelaria M 531
Canellos GP S1: 61
Cao S 1221
Capdevilla V S1: 103
Capello D 987, S2: 105
Capri G 1157
Capria S 175
Capron F 1009
Caputi V 1045
Caramatti C 1133
Carbone A S2: 89, 105
Carbone D 27
Carde P S1: 67, 111
Carella E 491
Carli PM S2: 49
Carlone S 1257
Carr BI 500
Cartwright R S2: 49
Casali P 1207
Casanova M 247
Casaretti R 291
Casassus P S1: 49
Cascinu S 169, 393
Castello G 385
Castiglione-Gertsch M 751, 825
Catalano V 393
Cavalli F 7, 214, 247, 251, 655, 727, 751, 931, 932
Cavina R 1157
Celesti F 175
Cellerino R 393
Cerny T 335, 510, 604, 655
Cerottini J-C 222, S2: 75
Cerri L 491
Cerroni L S2: 29
Cerruti A 385
Cerveri I S1: 19
Césarini J-P 435
Cesarman E S2: 123
Champlin R 515
Chan ACL S2: 41
Chanalet S 791
Chapiro J 714
Chatel M 791, 919
Chatelut E 607
Chaudhry A 1277
Chemaissani A 525
Chenard MP 405
Cherney B 987
Cheson BD S1: 119
Chevreau C 607
Chichmanian RM 919
Chin C 181
Christensen BE S2: 25
Christian MC S1: 119
Ciarmiello A 593
Ciatto S 297
Cipolla C 317
Clausen M S1: 57
Clayden D S2: 49
Clemm C 41
Clemons M 405, 616
Clodi K S2: 97
Coates AS 751, 825
Coates S 363
Cochlovius C S2: 83
Coeburgh JW S2: 49
Coiffier B 419, 701
Colajori E 155
Coleman RE 1243
Colleoni M 309
Collins J 751
Colombat P S1: 49
Comella G 169, 291, 649, 1045
Comella P 291, 1045
Comley M 271
Connors JM 979, 1125
Conroy T 575
Constenla DO 445
Conte PF 539, 939
Conter V 204, 247
Cooper IA S1: 71
Cooper N 807
Corazzelli G 593
Corbella F S1: 19
Corcoran MC S1: 133
Corda D 429
Corgna E 709
Cornu 714
Corsico A S1: 19
Cortés-Funes H 555
Cortesi E 745
Corvò R 773
Cosset JM S1: 67
Costantini M 1207
Cotter FE 979
Cottrell BJ 267
Court B 1089
Cowan KH 314
Crawford J 1117
Cremer FW 633
Crinò L 709
Crivellari D 751
Crump M 675
Cruz JJ 713
Culine S 951
Cunningham D 111, 415, 995
Cupissol D 951
Cvitkovic E 723, 1049
Cvitkovic F 575

D
D'Allens H 887
D'Aprile M 649
D'Incalci M 204, 343, 429, 1183

D'Lollo S S2: 49
Daamen S 695
Dalla-Favera R S2: 105
Dallavalle G 169
Dalley D 277
Damia G 343
Damstrup L 1197
Danesi R 539
Daniilidis J 451
Daponte A 291
Darwish S 709
Daus H S2: 83
De Boer CJ S2: 109
De Braud F 865
De Bruijn EA 1139
De Bruijn P 1145
De Grève J 691
De Iuliis A S2: 89
De Jong J 655
De Mulder P 695
De Pas M 865
De Rosa L 291
De Stoutz N 716
De Vivo A 583
De Vos AI 1145
de Vries EGE 812, 1053
De Wit M S1: 57
Dearnaley DP 37
Debrigode E 575
Deconinck E S1: 49
Degan M S2: 89
Degani D S1: 77
DeGuzman N 79
Deisseroth A S2: 59
Del Tacca M 539
Del Valle F S1: 85
Delwail V S1: 49
deMetz C 1277
Demicheli R 1075
Dempsey E 181
Denis LJ 814
Depierre A 615, 887, 1009
Derquenne F 714
Desablens B S1: 49
Despax R 463
Devizzi L S1: 53
Di Bacco A 469
Di Felice G 497
Diacomanolis E 195
Dieck C S1: 37
Diehl V 143, S1: 139, S2: 131
Diergarten K 355
Dietrich P-Y 820
Dimeo F 1251
Dimery IW 85
Dimopoulos MA 195, S2: 59
Dinopoulou M 451
Diverio D 1273
Dombros N 451
Doré J-F 435
Dornoff W 525
Dowsett M 631
Dreger P 401
Drent M 905
Drings P 457, 525
Drudi G 1263
du Bois A 355
Dubbelman R 801
Ducreux M 575
Dufresne J 675
Dugay J S1: 49
Dührsen U 1167
Dulguerov P 681
Dumontet C 701
Dunlop D 604
Dunn SM 857, 877
Durcreux M 500
Duro M 169
Duvic M S2: 59
Dziem G 1117

E
Eary J S1: 133
Eastell R 1243
Eckardt JR 1003
Edelstein MB 1139
Edmonson JH 637
Egbring R 781
Eisenhauer EA 963
Ekström K 163
El-Warith A 663
Ellenbogen S 405
Enander L-K 163
Engelhardt R 49, 57, 200
Engels K 271
Engenhart R 243
Engert A S1: 139
Epelbaum R 604
Eriksson B 685, 1041
Espina BM 79
Espinouse D 701
Esposito M 385
Eton O 363
Ezzat A 663

F
Fabbro M 951
Fagotti A 343
Falcone A 539
Falini B 583, S2: 101
Fallowfield L 616
Farris A 745
Fazi P 1273
Feller AC S2: 83
Feller N 957
Felman P 701
Ferrandina G 343
Ferrari L 649
Ferrari S 765, 1107
Ferrario L 317
Ferreri AJM 227
Fetscher S 49, 57, 1251
Feuring-Buske M S2: 55
Fey MF 751
Fiebiger WCC 797
Fiorentini G 169
Fischer JR 457
Fisher C 37, 1099
Fizai K 1089
Fizzotti M S2: 101
Flenghi L S2: 101
Flores A 247
Fogliata-Cozzi A 6
Fonseca E 713
Fontaine C 691
Fopp M 251
Forbes J 751
Forman A 515
Fornier M 497
Forster J 615
Fossa S 695
Fountzilas G 373, 451, 697, 1213
Fournel P 1009
Foussard C S1: 49
Fox RM S1: 71
Fox SB 271
François E 500, 575
François S S1: 49
Franchini M S1: 77
Frasci G 291, 1045
Fraternali-Orcioni G 583, 1133
Freeman LM 301
Frenay M 791, 919
Frezza G 883
Friedlander M 277
Fritsche HA 85
Frommhold H 49, 57
Frongillo R 1133
Frontini L 169
Fryer D 439
Fryer JG 439
Fujie T 369
Fulfaro F 1157

G
Gabriele A 969
Gahn B S2: 55
Gahrton G 219
Gaidano G 987, S2: 105
Gallipoli A 291
Gallmeier WM 1031
Gamberi B 1133
Ganesan TS 294
Ganz PA 105

Garancini MP 227
Garewal H 1117
Garnier G 1009
Gasbarrini A 765
Gascoyne RD 979, 1125
Gasparini G 469
Gasparini M S1: 53
Gattei V S2: 89
Gatter KC 271
Gatti C 1159
Gelber RD 751, 825
Gennari A 939
Gennatas C 195
Gérard JP 575
Gerbaulet A 1089
Gerber M 807
Gerl A 41
Ghandour C S1: 49
Gherlinzoni F 379, 583, 883
Ghielmini M 811
Ghilezan N 155
Giaccone G 957
Giannakakis T 1213
Gianni AM 933, 1176
Gianni L 503, 1157, 1263
Giannini O 1168
Giardiello FM 1151
Giardini R 497
Gicquel C 423
Gill PS 79
Gillan ER S1: 25
Giorgi D 297
Giovannini M 887
Girouard C 675
Gisbertz IAM S2: 33
Giunciuglio D 1257
Glass B 401
Glimelius B 163
Gloghini A S2: 89, 105
Gmuer J 251
Godard P 911
Goedhals L 615
Goldhirsch A 655, 751, 811, 825, 865, 936
Golding PF 259
Goldoni A 583
Goldschmidt H 633, 243
Goldstein D 871
Goldwasser F 1049
Gómez-Bernal A 713
Gómez-Codina J 547
Goossens A 691
Gore ME 445, 463
Gorga G 969
Gottardi O 169
Graf W 163
Grandi AM 705
Grandi C 1157
Grant SC 1269
Gratwohl A 251
Gravina A 291, 1045
Gregory WM 327
Greiner TC 979
Greinix H 1229
Gressin R S1: 103
Grill JP 637
Grim J 27
Grothaus-Pinke B S1: 85
Gruss H-J S2: 89
Guasti L 705
Guevin RM 181
Guida G 745
Guillory-Perez C 85
Guimbaud R 607
Guo D 1277
Gutiérrez MI 987
Gutierrez T 247
Gwyther S 463

H
Haag K 200
Haas R 243
Haaxma-Reiche H 812
Haegele P 919
Hagemeister F S1: 129
Hagenbeek A S1: 67, 111
Haglund U 163
Haie-Meder C 1089
Hainsworth J 181
Hamilton CR 259
Hanauske A 604
Hannoun-Levi 575
Hansen M 643
Hansmann M-L S2: 79
Hanson J 915
Harmer CL 1099
Harper PG 1139
Harrington KJ 669
Harris AL 271, 294
Harris C 27
Harris M 405
Harris NL S2: 11
Harstrick A 917, 1221, 1229
Hartmann JT 531
Hasenclever D 143
Hasse J 49, 57
Havemann K 27
Hayes S 616
Hebart H 1163
Hédouin M 887
Heelan RT 1269
Hegenbart U 243
Heidtmann H-H 781
Heinrichs V 1167
Hejna MH 797
Helmerhorst TJ 351
Henk JM 445
Henry-Amar M S1: 111
Henry D S3: 7
Hentrich M 41
Herbst K 1167, S1: 57
Hernández-Bronchud M 91
Hernberg M 71
Herranz C 547
Herrmann R 139
Heuman R 163
Hidalgo M 555
Hiddemann W 917, S1: 85, S2: 55
Highley MS 1139
Hilkens PHE 187
Hill ME 445
Hilsenbeck SG 1063
Hirsch FR 1284
Ho FCS S2: 41
Ho J S2: 41
Ho P S1: 119
Hoekman K 163, 957, 1235
Hofstra LS 812, 1053
Hohaus S 243
Hohenberger P 1163
Holden L 477
Holmberg L 235, 685, 757
Honegger HP 785
Hong WK 85
Honkoop AH 957
Hoppe RT S1: 115
Hoppin EC 503
Horning S 601
Horsman DE 979
Horwich A 37
Hoser G S1: 31
Hoskins PJ 181, 1125
Hossfeld DK 1167, S1: 57
Howell A 405, 616
Hoy JF 871
Huddart R 37, 302
Hudson IR 463
Hudson MM 215
Huidobro G 555
Hürny C 825
Husband J 37
Hutchison RE S1: 37, S2: 3

I
Iacobelli S 745
Imam H 1041
Immel A 781
Improta S S2: 89
Imrie K 675
Iorio D 1263
Irtelli L 745
Iveson T 995
Izbicka E 1063

J
Jack A S2: 49
Jacky E 251
Jacob MC S1: 103
Jacobs JA 905
Jacoulet P 1009
Jaehde U 1163
Jaffe ES S1: 83, S2: 17
Jankovic M 97
Janser JC 919
Janson ET 685
Jelić S 739
Jiménez-Lacave A 463
Jirillo A 649
Johnson KA 1151
Johnson PWM S2: 65
Joncourt F 335
Jones AR 1277
Jones SE 137, 1117
Jonkers DMAE S2: 33
Joshi B 79
Jost LM 785
Jovanović V 739
Jox A S2: 131
Judson IR 604, 1099

K
Kaern J 803
Kahraman T 1053
Kairies M 1163
Kaiser G 1031
Kaldor JM 871
Kalofonos H 1213
Kalogera-Fountzila A 451, 1213
Kaluzinski L 887
Kamphorst W 1023
Kanz L 49, 57
Kanzler H S2: 79
Kaplan S 604
Kappauf H 1031
Karavasilis V 811
Karlsson G 757
Kaye S 695
Keating A 675
Kellokumpu-Lehtinen P 525
Kerl H S2: 29
Kerr D 500
Kerr J 259
Kerz H 1163
Ketterer N 701
Keul J 1251
Keuning JJ 203
Khial F 911
Kiel K 633
Kies MS 417
Kindler H 1269
Kirsch IR S2: 45
Kjaer M S3: 15
Klasa R 1125
Klassen J 1277
Kleisbauer JP 1009
Klersy C S1: 19
Kliche KO S2: 97
Kloth DD 611
Kluin-Nelemans JC S1: 67
Kluin PM S2: 109
Knoppel E S1: 25
Knowles DM S2: 119, 123
Koch P 143, S1: 85
Kocik J S1: 85
Kodama F S1: 107
Köhne CH 917
Kornek GV 797
Kosmidis PA 373, 451, 697, 1213
Kovčin V 739
Kover PE 611
Kramar A 951, 1089
Krammer PH 457
Kraus J 1031
Kreačić M 739
Kreisman H 1117
Krenacs L S2: 17
Kreuser ED 1163
Kris MG 1269
Kristensen G 803
Krook JE 181
Kruglyak E 301
Kuczyk MA 531
Kudoh I S1: 107
Kühnel HJ 204
Kumagai K S1: 107
Küppers R S2: 79
Kura Y S1: 107
Kurkure PA 893
Kurtz JM 681
Kuse R 401
Kvols LK 637

L
Labianca R 169
Lacerda JF S2: 137
Lafitte JJ 1009
Lagrange JL 791
Lahm H 457
Lambert HE 327
Lamerz R 41
Lamy T S1: 49
Landoni F 969
Lange W 49, 57
Langenaeken C 745
Lassus M 155
Latagliata R 175, 1273
Lathan B 143
Laver J S1: 37
Law MG 871
Lawlor P 915
Lazzi S 1133
Le Cesne A 191
Le Chevalier T 191
Le Mevel A S1: 49
Le N 1125
Lebeau B 887, 1009
Lebouc Y 423
Lebrun C 791, 919
Leclerc JP 1009
Lee JJ 85
Leek J S2: 65
Legha SS 363
Legouffe E S1: 103
Lehmann W 681
Lencioni M 539
Leonard RCF S3: 3
Leoncini L 583, 1133
Leroux D S1: 103
Lerza R 385
Levi J 277
Levine AM 79
Levine M 217
Lianes P 555
Liberati A 117, 1059
Liberati F 1133
Licitra L 1157, 1207
Lieberz D 143
Liippo K 525
Liljegren G 235, 757
Linch DC S1: 63
Lindeman J 1023
Lindgren A 235
Lindtner J 751
Link MP S1: 37
Linné T 163
Lioure B 405
Lippman SM 85
Lips CJM 1015
Liso A S2: 101
Lissoni A 969
Lister TA S1: 89
Lo Coco F 1273
Loeffler M 143
Löffler H 401
Lofters WS 181
Loftin U S2: 83
Lokich JJ 15, 439
Lokiec F 1049
Long HJ 637
Long JD 198
Loos WJ 1145
López-Brea M 555
López-López J 555
Lorigan PC 97
Los M 1015
Lotz JP 714
Lück H-J 355
Lumley T 277

Lund B 643
Luporini G 169
Lusinchi A 575
Luthra R S2: 59

M
Maassen van de Brink KI 905
Mabry M 27
Maclean M 857
MacLennan KA S2: 65
Maes RAA 1139
Maestu I 547
Mafifoli L S1: 53
Magagnoli M 379, 883
Magrath IT 893, 987, S1: 7
Mahjoubi M 1049
Maisonneuve H S1: 49
Maisonneuve P 469
Malagnino F 1273
Maloisel F 405
Malta A 247
Malvaldi G 539
Mancuso S 343
Mandard A S1: 111
Mandelli F 175, 1273
Manegold C 525
Mangioni C 343, 969
Mann BS 637
Manzanal A S2: 37
Margrie S 277
Markham AF S2: 65
Markman M 937
Marradi P S1: 77
Martín G 713
Martignoni G 169
Martinelli G 655, 811
Martinetti A 649
Martoni A 155
Masera G 97, 204, 247
Massey A 995
Massin F 1009
Mathew P S1: 37
Matolcsy A S2: 119
Matthews JP S1: 71
Mattson K 525
McBride JA S2: 59
McCormack M 669
McGuire WP 311
McKeage MJ 485
McLaughlin P S1: 129
McNally R S2: 49
McQuade B 615
Mead GM 259, 267
Meerpohl H-G 355
Meerwaldt JH S1: 67
Mencoboni M 385
Meneghini V S1: 77
Merad M 191
Mercuri M 765, 899, 1107
Merla E 379, 883
Merlano M 773
Mertelsmann R 49, 57, 200, 1251, S3: 1, 11, 13
Merz H S2: 83
Mesiti M 745
Mesurolle B 191
Metzger U 626
Michel F-B 911
Migliazza A S2: 105
Mihalas S 195
Mijch AM 871
Milanović N 739
Milathianakis C 373
Miller VA 1269
Milleron B 1009
Millward MJ 485
Milne AE 259
Milpied N S1: 49
Minchella I 865
Minotti V 709
Mirabel X 575
Miralbell R 681
Misset JL 1049
Mitchell G 302
Mitrović L 739
Mittelmeier H-O 1031
Möbus V 355
Mocharnuk R 79
Möller E S1: 85
Möller P S2: 83
Momerency G 1139
Mondin R 149, 616
Monfardini S 593, S1: 111
Montalar J 547
Montalban C S2: 37
Montefusco E 175
Monti S 865
Montserrat E S1: 93
Moolenaar WH 801
Moos M 633
Moquin J-P 181
Morandi E 705
Morgan G S2: 49
Morgenstern GR 97
Mori M 369, 491
Moro D 1009
Morris SW S1: 37, S2: 59
Morrow C 314
Mosconi AM 709
Moullet I 701
Mross K 1167
Muñoz A 713
Muhonen T 71
Munárriz B 547
Munksgaard L S2: 25
Murphy SB S1: 37
Mustacchi G 745
Myara A 1049
Mylonakis N 697

N
Nair CN 893
Nakamura H S1: 107
Nakamura S S1: 107
Narang PK 807
Nardini P 745
Naresh K 893
Nasca S 575
Natale M 1045
Naukkarinen A S2: 49
Navari R 181
Neef J S2: 55
Neefe J 363
Neidhardt-Berard EM 701
Nelstrop AE 327
Newlands ES 477
Ng KK 1269
Nicholls J 37
Nicol SJ 807
Nicolaou A 451
Nicolella GP 1045
Noberasco C 649
Nolè F 865
Noonan DM 1257
Noordijk EM S1: 67, 111
Nooter K 1145
Nordgren H 235
Norman AR 37, 111, 995
North L S1: 129
Norum J 65, 1081
Novelli-Fischer U 1251
Numico G 773

O
O'Brien SM 807
O'Byrne KJ 294
O'Callaghan A 259
O'Leary J 1133
O'Neill A 751
O'Reilly RJ S2: 137
O'Reilly S 1151, 1125
Oates J 111, 995
Öberg K 685, 1041
Oberli A 335
Oberling F 405
Ocampo E 247
Ochs A 200
Ohnoshi T S1: 107
Oliani C 169
Olsen JA 65, 1081, S2: 49
Oltra A 547
Olver IN 277, 485, 615
Ong ST S1: 1, 5, S2: 1
Onienaoum A 1213
Oprić M 739

Ozols RF 611

P

Pacheco C 247
Pacilio C 1045
Pacini P 745
Padhani A 995
Padiglione A 871
Pagani L 491
Pagani O 655, 751
Page J 277
Pagliaro L 117
Pai S 893
Palacios R 247
Palladino MA 709
Palmer M 181
Palmeri S 1159
Paluchowska B 37
Palumbo R 1159
Pancera G 169
Panizzoni GA 469
Pannacciulli I 385
Pantolony D 675
Panza N 1045
Panzini I 1263
Papadimitracopoulou V S2: 59
Papadimitriou C 195
Papadopoulos N 363
Paquis P 791
Pardal JL 713
Paris A 911
Parwaresch R S1: 85
Parziale A 291
Paska W 615
Pasqualucci L S2: 101
Pasquini E 503, 1263
Pastor M 547
Pastore C S2: 105
Pate O S1: 129
Pater JL 181
Pavanato G 169
Pavlidis N 451, 697, 811, 1213, 1281
Pawinsky A 695
Pawlita M S2: 131
Paz-Ares L 555
Peccatori F 811
Pectasides D 1213
Pedersen NT S2: 25
Peiffert D 575
Pendjer I 739
Péne F 714
Peoch M S1: 103
Pereira J 915
Perevodchikova N 155
Perin V S2: 89
Perona G S1: 77
Perren T 569
Perrin J-L 1089
Peters FPJ 905
Peterson HF 825
Petit T 919
Petrella T S2: 49
Petti MC 175, 1273
Peyrade F 919
Pfanner E 539
Pfreundschuh M 143, S1: 85, S2: 83
Pham F 85
Piazza E 169
Piccaluga PP 583, 1133
Piccart MJ 1177
Picci P 765, 899, 1107
Piccioli M 583, 1133
Pick TE S1: 37
Pieri F 583
Pignon JP 575
Pileri SA 583, 883, 1133, S2: 101
Pinedo HM 957
Pinguet F 951
Pinna A S1: 111
Pinotti G 705
Pinto A S2: 89
Pinto D 765
Piron D 1089
Pizzo B 1269
Pluda JM S1: 119
Poggi S 1133
Poletti V 883
Pont J 1229
Poon M-C 1277
Popescu RA 415, 995
Porrozzi S 709
Prakash O 79
Prakash Purohit O 1243
Prendiville J 111, 995
Presant CA 203
Prescott RJ 569
Press OW S1: 133
Preti A S1: 129
Preusser P 917
Price K 751
Prince HM 675
Propper DJ 285, 294
Pugh WC S2: 59
Puitinen J S2: 49
Pujol H 951
Pujol J-L 911, 951
Pupa MR 1117
Pyrhönen S 71

Q

Quantin X 911
Quinn KJ 569
Quoix E 1009

R

Radaelli U 469
Raderer M 503, 797
Raemaekers J S1: 111
Raffeld M S2: 17
Raffo P 1159
Rahal M 663
Raina A 169
Raja MA 663
Rajewski K S2: 79
Ranfaing E 1009
Rashid H 198
Ratain MJ 807
Ravaioli A 503, 1263
Raymond E 1003, 1063
Redondo C S2: 37
Reers B S1: 85
Reggiardo G 385
Reiter A S1: 31
Reme-Saumon M 911
Reni M 227
Renstrup J 1041
Retsky MW 1075
Revhaug A 65
Reynés G 547
Rhys-Evans P 445
Ricci P 883
Ricci S 525
Ricetti M S1: 77
Richardson G 485
Ridwelski K 1163
Rintoul R 669
Ristović Z 739
Riva L 247
Rivera F 555
Rives RK 503
Rivière A 887, 1009
Rizzari C 204
Roberts P S2: 65
Roberts T 695
Robertson TI S1: 71
Rocca A 491
Rodenhuis S 351, 801
Rodríguez CA 713
Rodriguez G 1003
Rodriguez MA S1: 129
Roelvink M 604
Roessle M 200
Roggero E 727, 811
Rohen C S2: 131
Roila F 615
Romaguera J S1: 129
Romieu G 951
Rosenberg P 803
Ross PJ 111, 995
Rossi JF S1: 103
Rosso R 773
Roth J 27
Rothenberg ML 837
Rougier P 500, 575

Rowinsky EK 1003
Rozman C S1: 93
Rudenstam C-M 751, 825
Rude Voldborg B 1197
Ruether BA 1277
Rüffer U 143
Ruijgrok EJ 1145
Ruiz A 555
Russell JA 1277
Rustin GJS 327, 477
Rustum YM 1221

S
Sabattini E 583
Sacchini D 491
Sacco C S2: 89
Saglio G S2: 105
Saijo N 27
Sala A 247
Salisbury AJ 294
Salles G 419, 701
Samantas E 451, 697
Sánchez P 713
Sanger WG 979
Sangiorgi L 899
Sanguineti G 773
Santi L 1257
Santoro A 497, 1207, S1: 53
Sanz-Ortiz J 555
Sarris AH S1: 129, S2: 59
Sartori S 503, 1263
Saunders MP 294
Sawada K S1: 107
Sawada U S1: 107
Scambia G 343
Scarffe JH 97
Scartozzi M 393
Schäfer C S2: 55
Schönenberger-Berzins R 1168
Schaefer B 604
Schaefers MCW 351
Scheithauer W 503, 797
Schieppati G 649
Schilsky RL 807
Schindel M 457
Schlumberger M 423
Schmeller N 41
Schmid L 251
Schmitz N 401
Schmoll H-J 531, 917
Schnell R S1: 139
Schots R 691
Schouten HC S2: 33
Schrijvers D 1139
Schuchmann S 1163
Schuurhuis G-J 957
Schuuring E S2: 109
Schwartz EL 139
Schwenn M S1: 37
Sederholm C 525
Seeber S 917, 1221
Seitz J-F 575, 615
Seitz R 781
Selby PJ S2: 65
Sellner F 1229
Sellström H 163
Senn H-J 751, 825
Sensebe L S1: 49
Sessa C 247, 414, 618, 655, 929, 969
Seymour L 500
Sharma A 1063
Sharma S 1063
Shenkier T 1125
Shimano S S1: 107
Shipp MA S1: 43
Shoemaker D 1117
Shuster JJ S1: 37
Sieber M 143
Sikic BI 601
Silvestri D 247
Simes RJ 277
Similowski T 714
Simmonds PD 259, 267
Simmons T 363
Simoncini E 751
Simonetti RG 117
Sjödén P-O 163
Skarlos D 373, 451, 697, 1213
Skoog LA 807
Skovgaard-Poulsen H 27, 1197
Smartt P 259
Smith L 1003
Smolinski S 611
Smyth JF 569, 604
Snell V S2: 97
Soda H 1063
Soete G 691
Somers R S1: 67
Sommelet D 630
Sonnen R 401
Sorbe B 803
Sørensen JB 513
Sorensen JM S1: 119
Soria J-C 1089
Sotto JJ S1: 103
Spadea A 1273
Spang-Thomsen M 1197
Sparreboom A 1145
Srivastava G S2: 41
Stahel RA 27, 525, 785
Stathopoulos G 451
Stefanetti C 883
Sternberg CN 695, 1058
Stewart AK 675
Stewart DA 1277
Stewart DJ 615
Stieglitz R-D 1251
Stockbrügger RW S2: 33
Stoiber F 1229
Stoll BA 223
Stone J S1: 71
Stoter G 187, 1145
Strauss G 643
Streit M 1163
Stremetzne S 1163
Stridsberg M 685
Strohbach F 1163
Strumberg D 917
Stupp R S1: 1, 5, S2: 1
Suen Y S1: 25
Sugimachi K 369
Sun D 1063
Sureda A 91
Sutherland JA 1277
Svensson C 163
Swartzendruber DE 1075
Swedlow SH S2: 71
Sweetenham JW 259
Swiercz P S1: 103
Swinbank K S2: 65
Sykora KW S1: 31
Syrigos KN 669

T
Tabár L 235
Tabernero JM 555
Tagliabue G 343
Takagi T S1: 107
Takahashi T 27
Talbot DC 285, 294
Tarenzi E 1157
Tassinari D 503, 1263
Tattersall MHN 277, 857
Taylor M 294
Tecchio C S1: 77
Tedeschi M 569
Templeton D 79
ten Bokkel Huinink W 351, 463, 525
Teodorovic I S1: 67
Terpstra L 1015
Tesch H 143
Thürlimann B 751
Théodore C 1089
Theodorsson E 685
Thiel E 1163
Thomas E S2: 97
Thomas H 669
Thomas J S1: 67, 111
Thomas JM 1099
Thyss A S1: 103
Tichelli A 251
Tiemann M S1: 85
Tienghi A 765
Tobler A 251

Todeschini G S1: 77
Todesco M S2: 89
Tolino G 385
Toma S 1159
Tomino R S2: 49
Tomita D 1117
Tonato M 709
Tondini C 497
Torri V 1059
Torromeo C 1273
Tosello C 155
Trümper L S2: 83
Trivin F 1049
Troff C S2: 55
Tropé C 803
Tsavaris N 373
Tschopp J S2: 75
Tschopp L 251
Tulpule A 79
Tumolo S 969
Tura S 379, 583, 883
Turley H 271
Tuxen MK 643
Twentyman P 27

U
Ueo H 379
Uharek L 401
Ullrich B 811
Ultmann JE S1: 1, 5, S2: 1

V
Vaidya S 893
Valagussa P S1: 53
Valle J 405, 616
Valsecchi R 169
Van Besien K 515
Van Cauwenberghe K 1139
van den Bent MJ 187
Van den Berg H S1: 15
van der Burg MEL 627, 1145
van der Graaf WTA 812
Van der Valk P 1023
van der Vijgh WJF 957
van der Wall E 957
Van Glabbeke M 963
Van Groeningen CJ 957
van Halteren HK 203
Vanhoefer U 1221
Van Hoof A S1: 111
Van Krieken JHJM S2: 109
Van Oosterom AT 1139
Van Pawel J 525
van Rijswijk REN 1235
van Walree N 525
Van Warmerdam LJC 351
Vannozzi MO 385
Vats T 893
Vaughan Hudson B S1: 63
Vecht ChJ 187
Venco A 705
Venzon D 893
Verheijen RHM 1235
Verma S 181
Vermorken JB 957, 963, 1235
Veronesi P 317
Verrill MW 1099
Verweij J 187, 463, 1145
Viale G 469
Viale M 385
Viale P 491
Viaro D 155
Villa E 227
Villani G 1159
Vineis P 945
Vinholes JJF 1243
Vitale V 773
Viterbori P 1207
Viviani S S1: 53
Vlahos G 195
Voest EE 1015
Vogelzang NJ 807
Voillat L 405
Voinea A 714
Vokes EE 417
Volpini E S1: 19
Von Bonin F S2: 83
Von Fliedner V 251
Von Hoff DD 1003, 1063
von Neuhoff N 401
von Roemeling R 363, 1269
Vonen B 65
Vorbeck F 797
Vornanen M S2: 49
Votan B 887
Voulgaris Z 195
Vovk M S1: 111
Vreugdenhil G 203
Vrints LWMA S2: 33, 49

W
Waasdorp M S2: 59
Wadleigh RG 198
Wadler S 139, 301
Wagenaar SS 905
Wagenius G 525
Wagstaff J 957
Walde D 181
Walker P 915
Wallmeier M 243, 633
Waluch V 203
Wampler GL 439
Wannenmacher M 243
Warnecke S 1163
Warnke R 601
Warnke RA S2: 119
Wasserman E 1049
Watanabe S 915
Watson M 995
Weaver A 405
Webb A 111, 995
Weinlaender G 797
Weiss G 1003
Welte K S1: 31
Wenger M 49, 57
Westermann AM 801
Wheeler H 277
Whelan T 217
Whitefield M S2: 71
Whitehouse JMA 267, 259
Whitehouse RM 271
Wibault P 1089
Widmer L 785
Wijffels RTM 1053
Wilander E 685
Wilke H 917
Wilkinson JR 615
Wilkinson P 569
Willemse PHB 812, 1053
Williams CJ 511, 1185
Williams ME S2: 71
Williams SA S1: 25
Willich N S1: 85
Wilmanns W 41
Wilson K 181
Wiltshaw E 1099
Windle B 1063
Winkler U S1: 139
Wirth K 200
Wittebol-Post D 1015
Wolf J S2: 131
Wolf M 781, S1: 71
Wolf W 203
Woodings PL 97
Wörmann B S2: 55
Wouters EFM 905
Wright DH 267
Wünsch PH 1031
Wynne C 277

X
Xu WS S2: 41

Y
Ychou M 951
Younes A S1: 129, S2: 97

Z
Zaegel M 1009
Zagonel V S2: 89
Zalcberg J 485
Zallocco D 583
Zampino MG 865
Zaniboni A 169

Zanini M 497
Zanotti R S1: 77
Zanzi P 705
Zappa M 297
Zavatta M 899
Zee B 181
Zenz M S3: 1, 25
Zhang X S2: 97
Zhao S S2: 97
Zielinski C 155
Zilembo N 649
Zillig D 1163
Zimatore M 655
Zinzani PL 379, 583, 883, 1133
Zsiros J S1: 15
Zucca E 310, 422, 727, 1062
Zur Stadt U S1: 31
Zwaan F 663
Zwiebel FM 1163